Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
47.3 /100
Rank 12 out of 27 Sectors -
Advance/Decline
315/353
-
No. of Companies668
-
Avg. Market Cap7,047
-
Price to Earning Ratio6.16
-
Price to Earning Growth Ratio0.71
-
Price to Book Ratio22.73
-
Return on Equity44.89
-
Return on Capital Employed-
-
Return on Assets9.51
-
Dividend yield 1 year %0.83 %
-
Net Profit Growth Annual YoY %-22.55 %
-
Net Profit Growth Qtr YoY %-71.43 %
-
Net Profit Growth Qtr QoQ %-78.46 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
387,340.0
|
219.2
|
L
 0.1%
H
217.1
221.0
|
L
 0.5%
H
211.7
221.0
|
L
 -5.9%
H
211.7
234.7
|
L
 10.2%
H
196.9
244.8
|
L
 9.3%
H
163.8
244.8
|
L
 48.0%
H
131.0
244.8
|
L
 136.0%
H
94.7
244.8
|
L
 241.7%
H
50.7
244.8
|
| Adc Therapeutics SA |
|
454.5
|
4.0
|
L
 -2.9%
H
3.6
4.1
|
L
 -9.4%
H
3.6
4.4
|
L
 -6.3%
H
3.6
4.8
|
L
 53.0%
H
2.6
4.8
|
L
 37.9%
H
1.1
4.8
|
L
 -5.2%
H
0.4
6.0
|
L
 -87.6%
H
0.4
38.3
|
L
H
0.4
56.6
|
| Amneal Pharmaceuticals Inc |
|
3,574.3
|
11.4
|
L
 -2.5%
H
11.3
11.7
|
L
 5.1%
H
10.7
11.9
|
L
 9.8%
H
9.6
11.9
|
L
 38.5%
H
8.2
11.9
|
L
 32.1%
H
6.7
11.9
|
L
 383.8%
H
1.2
11.9
|
L
 175.3%
H
1.2
11.9
|
L
 -68.3%
H
1.2
45
|
| Annovis Bio Inc |
|
52.2
|
2
|
L
 0.5%
H
1.9
2.1
|
L
 -4.8%
H
1.9
2.2
|
L
 -11.5%
H
1.6
2.6
|
L
 -23.1%
H
1.6
3.0
|
L
 -76.8%
H
1.1
8.7
|
L
 -83.7%
H
1.1
23.9
|
L
 -57.0%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,463.9
|
6.7
|
L
 -0.6%
H
6.6
6.8
|
L
 -5.3%
H
6.6
7.1
|
L
 4.1%
H
5.9
7.2
|
L
 15.5%
H
5.7
8.7
|
L
 -29.4%
H
4.3
9.5
|
L
 -10.0%
H
4.0
11.5
|
L
 -60.0%
H
4.0
34.8
|
L
 -91.9%
H
4.0
119.9
|
| Bristol-Myers Squibb |
|
95,049.3
|
46.7
|
L
 0.1%
H
46.3
47.0
|
L
 1.4%
H
45.4
47
|
L
 4.6%
H
42.5
47
|
L
 2.9%
H
42.5
49.6
|
L
 -14.7%
H
42.5
63.3
|
L
 -41.0%
H
39.4
81.4
|
L
 -26.8%
H
39.4
81.4
|
L
 -28.7%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
533.6
|
10.2
|
L
 -1.1%
H
9.7
10.2
|
L
 -18.6%
H
9.7
12.7
|
L
 2.4%
H
9.0
13.4
|
L
 23.3%
H
7.5
13.4
|
L
 -7.6%
H
4.0
13.4
|
L
 -50.0%
H
1.4
20.5
|
L
 -89.0%
H
1.4
127.2
|
L
 -69.1%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
10,677.6
|
21.5
|
L
 -0.1%
H
20.8
21.6
|
L
 -3.0%
H
20.8
23.0
|
L
 5.1%
H
19.5
23.0
|
L
 30.4%
H
16.2
23.0
|
L
 48.2%
H
8.0
23.0
|
L
 59.8%
H
7.9
23.0
|
L
 -29.1%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK Plc ADR |
|
93,699.2
|
46.6
|
L
 -1%
H
46.4
46.9
|
L
 -0.5%
H
46.0
47.2
|
L
 7.2%
H
42.8
47.2
|
L
 24.1%
H
37.7
47.2
|
L
 27.2%
H
31.7
47.2
|
L
 46.0%
H
31.2
47.2
|
L
 24.3%
H
28.5
47.8
|
L
 9.3%
H
28.5
49.1
|
| Johnson & Johnson |
|
449,502.2
|
186.6
|
L
 -0.2%
H
185.7
188.4
|
L
 -1.2%
H
185.4
189.0
|
L
 -1.2%
H
184.7
194.5
|
L
 8.8%
H
170.4
194.5
|
L
 19.0%
H
140.7
194.5
|
L
 7.9%
H
140.7
194.5
|
L
 31.2%
H
140.7
194.5
|
L
 83.1%
H
94.3
194.5
|
| Eli Lilly |
|
827,328.5
|
924.4
|
L
 -1.4%
H
900.9
932
|
L
 7.1%
H
862.6
955.5
|
L
 9.6%
H
783.8
955.5
|
L
 44.2%
H
623.8
955.5
|
L
 15.9%
H
623.8
955.5
|
L
 153.2%
H
302.1
972.5
|
L
 547.6%
H
138.6
972.5
|
L
 1048.9%
H
64.2
972.5
|
| Merck & Company |
|
214,148.9
|
86.3
|
L
 0.6%
H
85.2
86.6
|
L
 0.4%
H
82.0
86.6
|
L
 -1.5%
H
82.0
88.8
|
L
 7.4%
H
77.6
91
|
L
 -14.7%
H
73.3
105.1
|
L
 -13.8%
H
73.3
134.6
|
L
 12.5%
H
68.4
134.6
|
L
 65.6%
H
45.8
134.6
|
| Nuvation Bio Inc Ordinary |
|
1,621.6
|
4.7
|
L
 -5.8%
H
4.5
5.0
|
L
 -9.4%
H
3.9
5.4
|
L
 29.2%
H
3.4
5.6
|
L
 102.1%
H
2.2
5.6
|
L
 80.5%
H
1.5
5.6
|
L
 125.2%
H
1.0
5.6
|
L
 -53.9%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk ADR |
|
202,978.1
|
45.7
|
L
 -1.8%
H
45.2
46.3
|
L
 -7.6%
H
45.2
49.9
|
L
 -22.6%
H
45.2
60.1
|
L
 -6.3%
H
45.2
62.3
|
L
 -57.6%
H
45.1
112.5
|
L
 -20.6%
H
45.1
148.2
|
L
 29.8%
H
32.9
148.2
|
L
 66.4%
H
15.5
148.2
|
| Novartis AG ADR |
|
242,439.4
|
126.4
|
L
 -0.2%
H
126
127.0
|
L
 2.1%
H
122.9
127.1
|
L
 -4.0%
H
121.6
133.2
|
L
 9%
H
115.8
133.6
|
L
 18%
H
96.1
133.6
|
L
 54.4%
H
80.0
133.6
|
L
 49.1%
H
74.1
133.6
|
L
 59.4%
H
59.2
133.6
|
| Organon Co |
|
1,762.6
|
6.8
|
L
 1.0%
H
6.4
6.8
|
L
 0.4%
H
6.3
6.9
|
L
 -36.0%
H
6.2
10.8
|
L
 -25.6%
H
6.2
11.3
|
L
 -57.9%
H
6.2
17.2
|
L
 -71.8%
H
6.2
32.4
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare |
|
2,953.4
|
60.0
|
L
 -2.3%
H
59.7
62.3
|
L
 -1.1%
H
59.5
62.3
|
L
 -4.6%
H
59.5
63.6
|
L
 -11.3%
H
59.5
68.6
|
L
 -25.2%
H
59.5
90.0
|
L
 4.8%
H
56.0
90.0
|
L
 81.4%
H
33.9
90.0
|
L
 24.1%
H
26.3
90.0
|
| Pfizer |
|
138,901.8
|
24.4
|
L
 0.0%
H
24.1
24.6
|
L
 -0.9%
H
24.1
25.2
|
L
 -7%
H
24.1
26.5
|
L
 0.8%
H
23.6
27.7
|
L
 -11.0%
H
20.9
27.7
|
L
 -48.1%
H
20.9
54.9
|
L
 -29.1%
H
20.9
61.7
|
L
 -24.0%
H
20.9
61.7
|
| Perrigo Company plc |
|
1,987.3
|
14.4
|
L
 -3.3%
H
14.2
14.9
|
L
 -30.4%
H
14.2
20.7
|
L
 -33.4%
H
14.2
22.0
|
L
 -36.8%
H
14.2
24.6
|
L
 -46.4%
H
14.2
30.9
|
L
 -63.2%
H
14.2
40.3
|
L
 -67.7%
H
14.2
50.9
|
L
 -91.1%
H
14.2
165.6
|
| Arcus Biosciences Inc |
|
2,389.2
|
19.3
|
L
 -1.3%
H
18.6
19.7
|
L
 -2.1%
H
18.6
20.7
|
L
 37.6%
H
14.2
22.1
|
L
 108.1%
H
8.9
22.1
|
L
 17.3%
H
6.5
22.1
|
L
 -15.9%
H
6.5
36.1
|
L
 -4.7%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr Reddys Laboratories ADR |
|
11,205.7
|
13.5
|
L
 -0.1%
H
13.4
13.5
|
L
 1.3%
H
13.4
13.5
|
L
 -4.1%
H
13.1
15.0
|
L
 -1.0%
H
13.1
15.1
|
L
 -10.8%
H
12.3
16.2
|
L
 19.3%
H
10.2
74.9
|
L
 0.9%
H
9.6
74.9
|
L
 25.8%
H
5.6
74.9
|
| Takeda Pharmaceutical Co ADR |
|
43,154.5
|
13.7
|
L
 0.2%
H
13.6
13.7
|
L
 1.6%
H
13.4
13.7
|
L
 -5.5%
H
13.0
14.4
|
L
 -4.9%
H
13.0
15.7
|
L
 -1.4%
H
12.8
15.7
|
L
 2.6%
H
12.6
17.2
|
L
 -18.2%
H
12.3
20.0
|
L
 -45.0%
H
12.3
30.6
|
| Teva Pharmaceutical Industries |
|
27,500.4
|
24.0
|
L
 -2%
H
23.6
24.4
|
L
 17.0%
H
20.1
25
|
L
 19.4%
H
18.8
25
|
L
 47.2%
H
16.1
25
|
L
 37.0%
H
12.5
25
|
L
 168.4%
H
7.1
25
|
L
 162.8%
H
6.8
25
|
L
 -60.2%
H
6.1
66.6
|
| Usana Health Sciences Inc |
|
349.7
|
19.1
|
L
 -0.2%
H
18.8
19.4
|
L
 -9.6%
H
18.8
21.6
|
L
 -27.4%
H
18.7
26.8
|
L
 -34.0%
H
18.7
32.3
|
L
 -52.8%
H
18.7
41.8
|
L
 -62.6%
H
18.7
69.6
|
L
 -75.3%
H
18.7
107.9
|
L
 -71.2%
H
18.7
138.0
|
| Zoetis |
|
52,989.0
|
120.2
|
L
 0.6%
H
117.3
120.3
|
L
 -16.6%
H
117.3
144.8
|
L
 -15.8%
H
117.3
148.3
|
L
 -18.9%
H
117.3
160.5
|
L
 -31%
H
117.3
181.9
|
L
 -12.8%
H
117.3
201.9
|
L
 -29.0%
H
117.3
249.3
|
L
 161.6%
H
38.3
249.3
|
| Biohaven |
|
873.8
|
8.3
|
L
 -3.2%
H
7.6
8.5
|
L
 -52.0%
H
7.6
16.5
|
L
 -45.0%
H
7.6
18.6
|
L
 -45.8%
H
7.6
18.6
|
L
 -84.4%
H
7.6
54.5
|
L
 -47.3%
H
7.6
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
97.6
|
2.1
|
L
 -1.4%
H
2.0
2.1
|
L
 -13.8%
H
2.0
2.4
|
L
 -6.8%
H
1.9
3.8
|
L
 20.4%
H
1.6
3.8
|
L
 -1.4%
H
1.4
3.8
|
L
 -84.1%
H
1.2
14.1
|
L
 -89.4%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,170.4
|
3.9
|
L
 -13.7%
H
3.4
4.0
|
L
 -29.6%
H
3.4
5.6
|
L
 -32.2%
H
3.4
6.5
|
L
 -7.8%
H
3.4
6.5
|
L
 41.7%
H
1.9
6.5
|
L
 -67.4%
H
1.9
15.0
|
L
H
1.9
71.9
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
215.4
|
4.2
|
L
 0.2%
H
4
4.2
|
L
 -12.7%
H
4
4.9
|
L
 -20%
H
4
5.7
|
L
 -33.0%
H
4
7.5
|
L
 -34.2%
H
3.9
7.5
|
L
 14.4%
H
2.2
9.0
|
L
 -83.7%
H
2.2
94.8
|
L
 -96.2%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,342.7
|
27.8
|
L
 -1.9%
H
26.5
28.4
|
L
 -1.5%
H
25.6
29.6
|
L
 34.9%
H
20.3
29.6
|
L
 103%
H
12.8
29.6
|
L
 8.7%
H
5.5
29.6
|
L
 12.3%
H
2.2
53.9
|
L
 -41.5%
H
2.2
66
|
L
 -97.6%
H
2.2
1505.5
|
| Acumen Pharmaceuticals Inc |
|
113.9
|
1.9
|
L
 -1.1%
H
1.7
1.9
|
L
 -14.9%
H
1.7
2.2
|
L
H
1.7
2.5
|
L
 32.4%
H
1.2
2.5
|
L
 -40.7%
H
0.9
3.4
|
L
 -71.0%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
862.6
|
4.5
|
L
 1.4%
H
4.3
4.5
|
L
 -4.9%
H
4.3
4.8
|
L
 4.9%
H
4.1
4.9
|
L
 32.4%
H
3.3
5.1
|
L
 20.6%
H
2.7
5.1
|
L
 85.2%
H
1.7
5.1
|
L
 61.3%
H
1.7
6.5
|
L
 -24.1%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
68.5
|
2.9
|
L
 2.5%
H
2.8
2.9
|
L
 3.9%
H
2.8
3.0
|
L
 -9.6%
H
2.8
3.3
|
L
 11.1%
H
2.5
3.4
|
L
 438.9%
H
0.4
5.5
|
L
 -61.2%
H
0.4
18.7
|
L
 -92.7%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
| Acadia Pharmaceuticals Inc |
|
3,818.4
|
22.6
|
L
 4.3%
H
21.6
22.7
|
L
 -0.6%
H
20.6
23.6
|
L
 4.8%
H
19.7
23.6
|
L
 -7.5%
H
19.7
26.7
|
L
 31.2%
H
13.4
26.7
|
L
 55.8%
H
13.4
33.9
|
L
 -55.0%
H
12.2
57.5
|
L
 -38.6%
H
12.2
58.7
|
| Adicet Bio Inc |
|
98.1
|
0.6
|
L
 -5.9%
H
0.6
0.7
|
L
 -14.7%
H
0.6
0.8
|
L
 -24.7%
H
0.6
1.1
|
L
 -7.3%
H
0.6
1.1
|
L
 -51.9%
H
0.5
1.4
|
L
 -96.7%
H
0.5
21.9
|
L
 -94.6%
H
0.5
21.9
|
L
H
0.5
147.7
|
| Achieve Life Sciences Inc |
|
234.6
|
4.6
|
L
 -3.2%
H
4.3
4.7
|
L
 -10.4%
H
4.3
5.3
|
L
 38.3%
H
3.0
5.8
|
L
 73.9%
H
2.4
5.8
|
L
 -8.2%
H
1.8
5.8
|
L
 121.7%
H
1.8
10.3
|
L
 -44.1%
H
1.8
16.1
|
L
 -99.9%
H
1.8
6160
|
| AC Immune SA |
|
332.0
|
3.3
|
L
 -4.4%
H
3.2
3.5
|
L
 -2.4%
H
3.1
3.7
|
L
 -8.1%
H
2.6
4
|
L
 58.7%
H
2.0
4
|
L
 0.9%
H
1.4
4
|
L
 10.4%
H
1.4
5.1
|
L
 -31.8%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
5,004.6
|
86.6
|
L
 -1.9%
H
84.5
88.1
|
L
 -4.1%
H
84
92.3
|
L
 1.6%
H
82.6
94.1
|
L
 21.6%
H
66.5
94.1
|
L
 -12.7%
H
47.9
107.4
|
L
 280.8%
H
18.7
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Aclaris Therapeutics Inc |
|
251.4
|
2.3
|
L
 2.2%
H
2.2
2.4
|
L
 -7.9%
H
2.1
2.7
|
L
 26.1%
H
1.7
2.7
|
L
 47.8%
H
1.6
2.7
|
L
 -5.3%
H
1.1
5.2
|
L
 -85.1%
H
0.6
19.0
|
L
 -43.7%
H
0.6
30.4
|
L
 -84.2%
H
0.6
33.9
|
| Acrivon Therapeutics Inc |
|
59.1
|
1.9
|
L
 -6%
H
1.8
2.0
|
L
 -5.5%
H
1.8
2.5
|
L
 -1.6%
H
1.7
2.5
|
L
 48.0%
H
1.2
2.7
|
L
 -77.9%
H
1.1
8.7
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharmaceuticals Inc |
|
21.0
|
1.2
|
L
 6.9%
H
1.1
1.2
|
L
 -7.5%
H
1.1
1.4
|
L
 -1.6%
H
1.0
1.5
|
L
 218.0%
H
0.4
1.5
|
L
 148%
H
0.4
1.5
|
L
 -42.1%
H
0.4
3.0
|
L
 -95.7%
H
0.4
58.8
|
L
 -98.7%
H
0.4
117.6
|
| Grace Therapeutics Inc |
|
45.4
|
3.0
|
L
 -1.6%
H
3.0
3.0
|
L
 -5.4%
H
3.0
3.2
|
L
 -1.0%
H
3.0
3.4
|
L
 1.4%
H
2.9
3.4
|
L
 -3.2%
H
1.8
5.0
|
L
 -6.3%
H
1.7
5.1
|
L
 -65.7%
H
1.7
58.6
|
L
 -97.5%
H
1.7
161.1
|
| Acurx Pharmaceuticals Inc |
|
9.8
|
4.7
|
L
 -5.4%
H
4.5
4.9
|
L
 -5.8%
H
4.5
5.6
|
L
 10.3%
H
4.5
8.3
|
L
 1.7%
H
3.8
8.3
|
L
 -87.4%
H
3.8
38
|
L
 -91.8%
H
3.8
176.4
|
L
H
3.8
176.4
|
L
H
3.8
176.4
|
| Adial Pharmaceuticals Inc |
|
7.2
|
0.3
|
L
H
0.3
0.3
|
L
 -5.7%
H
0.3
0.4
|
L
 -15.4%
H
0.3
0.4
|
L
 -15.4%
H
0.3
0.4
|
L
 -69.2%
H
0.2
1.3
|
L
 -95.7%
H
0.2
15
|
L
 -99.3%
H
0.2
127
|
L
H
0.2
236
|
| Adma Biologics Inc |
|
3,455.7
|
14.5
|
L
 3.5%
H
13.8
14.5
|
L
 -6.2%
H
13.8
15.7
|
L
 3.8%
H
13.8
16.1
|
L
 -13.3%
H
13.8
17.9
|
L
 -26.4%
H
13.5
25.7
|
L
 473.9%
H
2.5
25.7
|
L
 660.2%
H
1.0
25.7
|
L
 63.9%
H
1.0
25.7
|
| Adaptive Biotechnologies Corp |
|
2,257.9
|
14.8
|
L
 -5.0%
H
14.5
15.4
|
L
 -14.8%
H
14.5
17.8
|
L
 3.1%
H
14.4
17.9
|
L
 17.9%
H
11.8
17.9
|
L
 162.7%
H
4.3
17.9
|
L
 95.1%
H
2.3
17.9
|
L
 -71.2%
H
2.3
71.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
2.7
|
5.3
|
L
 -9.5%
H
5
5.8
|
L
 -20.6%
H
5
7.1
|
L
 -92.9%
H
5
84.4
|
L
 -96.1%
H
5
140.1
|
L
 -100.0%
H
5
438581.3
|
L
 -100.0%
H
5
3543680000
|
L
 -100.0%
H
5
10000000000
|
L
H
5
10000000000
|
| Adverum Biotechnologies Inc |
|
95.0
|
4.3
|
L
 0.9%
H
4.3
4.3
|
L
 0.5%
H
4.2
4.4
|
L
 -12.6%
H
4.0
5.6
|
L
 76.3%
H
2.2
5.8
|
L
 -45.3%
H
1.8
8.2
|
L
 -94.4%
H
1.8
297
|
L
 -99.6%
H
1.8
1479
|
L
 -99.5%
H
1.8
2698
|
| Agenus Inc |
|
126.8
|
4.0
|
L
 3.7%
H
3.7
4.0
|
L
 0.3%
H
3.6
4
|
L
 -6.4%
H
3.6
4.6
|
L
 -16.4%
H
3.6
5.2
|
L
 1.3%
H
1.4
7.3
|
L
 -91.5%
H
1.4
196
|
L
 -94.7%
H
1.4
196
|
L
 -95.6%
H
1.4
196
|
| Agios Pharmaceuticals Inc |
|
2,371.6
|
40.7
|
L
 0.9%
H
39.4
41.5
|
L
 -5.9%
H
38.9
44.1
|
L
 -0.5%
H
38.9
44.3
|
L
 9.7%
H
32.7
44.3
|
L
 -26.2%
H
23.4
62.6
|
L
 50.0%
H
19.8
62.6
|
L
 3.7%
H
16.8
62.6
|
L
 -46.4%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
91.2
|
22.5
|
L
 0.6%
H
21.1
22.5
|
L
 -7.9%
H
21.1
24.5
|
L
 40.6%
H
16.0
25.1
|
L
 47.8%
H
14.5
25.1
|
L
 48.4%
H
13.9
25.1
|
L
 -28.5%
H
2.7
39
|
L
 -89.1%
H
2.7
247.5
|
L
H
2.7
318.8
|
| Akebia Therapeutics Inc |
|
540.9
|
2.0
|
L
 1.5%
H
2.0
2.1
|
L
 -7.7%
H
2.0
2.2
|
L
 -30.9%
H
2.0
3.2
|
L
 -32.2%
H
2.0
3.4
|
L
 9.7%
H
1.5
4.1
|
L
 603.4%
H
0.2
4.1
|
L
 -14.3%
H
0.2
5.1
|
L
 -80.1%
H
0.2
20.3
|
| Akero Therapeutics Inc |
|
4,332.1
|
54.0
|
L
 0.2%
H
53.9
54.1
|
L
 -0.3%
H
53.9
54.2
|
L
 17.5%
H
45.9
54.5
|
L
 7.1%
H
41.8
54.5
|
L
 55.0%
H
21.3
58.4
|
L
 41.6%
H
11.3
58.4
|
L
 87.3%
H
7.5
58.4
|
L
H
7.5
58.4
|
| Avalon GloboCare Corp |
|
7.9
|
2.1
|
L
 1.5%
H
1.9
2.1
|
L
 -3.3%
H
1.9
2.1
|
L
 -14.2%
H
1.9
2.5
|
L
 -13.1%
H
1.9
2.9
|
L
 -40.4%
H
1.9
11.7
|
L
 -63.5%
H
0.2
11.7
|
L
 -82.0%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
282.2
|
4.7
|
L
 -2.5%
H
4.5
4.8
|
L
 -7.5%
H
4.5
5.3
|
L
 -16.4%
H
4.5
5.8
|
L
 -9.3%
H
4.5
6.2
|
L
 -12.2%
H
1.1
7.2
|
L
 -11.8%
H
1.1
12.0
|
L
 -29.8%
H
1.1
16.0
|
L
 -37.3%
H
1.1
16.7
|
| Alector Inc |
|
131.3
|
1.3
|
L
 -1.5%
H
1.2
1.3
|
L
 -12.9%
H
1.2
1.5
|
L
 -58.3%
H
1.2
3.4
|
L
 -12.3%
H
1.2
3.4
|
L
 -77.3%
H
0.9
6.1
|
L
 -84.8%
H
0.9
9.9
|
L
 -88.7%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
49.1
|
7.1
|
L
 -0.4%
H
6.2
7.2
|
L
 -14.3%
H
6.1
8.5
|
L
 -28.2%
H
6.1
11.2
|
L
 -13.0%
H
6.1
11.7
|
L
 -31.0%
H
3.8
46.3
|
L
 -71.3%
H
3.8
60.3
|
L
 -98.1%
H
3.8
937.8
|
L
H
3.8
937.8
|
| Alkermes plc |
|
5,430.7
|
32.9
|
L
 3.8%
H
31.4
33.0
|
L
 7.1%
H
29.7
36.3
|
L
 6.3%
H
28.4
36.3
|
L
 23.7%
H
25.2
36.3
|
L
 13.5%
H
25.2
36.5
|
L
 41.0%
H
22.0
36.5
|
L
 93.5%
H
16.9
36.5
|
L
 -54.3%
H
12.0
80.7
|
| Allogene Therapeutics Inc |
|
261.8
|
1.2
|
L
 12.4%
H
1.0
1.2
|
L
 -4.8%
H
1.0
1.3
|
L
 -12.6%
H
1.0
1.5
|
L
 12.4%
H
1.0
1.5
|
L
 -63.0%
H
0.9
3.8
|
L
 -87.0%
H
0.9
11.1
|
L
 -95.8%
H
0.9
39.1
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
16.7
|
1.2
|
L
 3.6%
H
1.1
1.2
|
L
 -20.7%
H
1.1
1.4
|
L
 -34.3%
H
1.1
1.8
|
L
 16.2%
H
0.8
2.1
|
L
 -17.9%
H
0.6
2.1
|
L
 -100.0%
H
0.1
37800
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharmaceuticals Inc |
|
58,486.8
|
442.7
|
L
 0.5%
H
430.8
443.7
|
L
 -2.9%
H
417
457.3
|
L
 -3.7%
H
417
495.6
|
L
 1.8%
H
417
495.6
|
L
 62.6%
H
205.9
495.6
|
L
 116.0%
H
142.0
495.6
|
L
 238.6%
H
117.6
495.6
|
L
 336.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
41.5
|
1.6
|
L
 2.6%
H
1.5
1.7
|
L
 2.6%
H
1.4
2.2
|
L
 11.1%
H
1.2
2.2
|
L
 44.1%
H
1.1
2.2
|
L
 -57.0%
H
1.0
4.0
|
L
 -60%
H
1.0
7.4
|
L
 -92.9%
H
1.0
46.6
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
428.8
|
4.1
|
L
 4.3%
H
3.8
4.2
|
L
 1.5%
H
3.7
4.2
|
L
 4.6%
H
3.7
4.3
|
L
 16.8%
H
3.3
4.3
|
L
 -44.9%
H
2.9
11.2
|
L
 -64.7%
H
2.1
17.2
|
L
 -67.0%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
| Alvotech |
|
1,779.2
|
5.7
|
L
 12.9%
H
5.4
5.7
|
L
 -25.4%
H
4.7
5.9
|
L
 -33.9%
H
4.7
9.0
|
L
 -32.4%
H
4.7
9.3
|
L
 -54.9%
H
4.7
13.7
|
L
 -6.5%
H
4.7
18
|
L
H
4.7
18
|
L
H
4.7
18
|
| Kalaris Therapeutics Inc |
|
88.8
|
4.8
|
L
 0.4%
H
4.5
4.8
|
L
 -5.6%
H
4.5
5.5
|
L
 -38.5%
H
4.3
8.2
|
L
 75.3%
H
2.1
8.8
|
L
 384.7%
H
0.4
12.9
|
L
 -38.5%
H
0.4
12.9
|
L
 -85.9%
H
0.4
49.0
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
9.0
|
2.4
|
L
 -5.6%
H
2.3
2.5
|
L
 -5.9%
H
2.3
2.6
|
L
 -4.4%
H
2.1
2.7
|
L
 6.3%
H
2.1
2.7
|
L
 -82.4%
H
2.1
14.3
|
L
 -99.8%
H
2.1
1782
|
L
H
2.1
45292.5
|
L
H
2.1
45292.5
|
| Amgen |
|
172,421.5
|
320.2
|
L
 1.5%
H
314
321.4
|
L
 7.3%
H
292.1
323.0
|
L
 8.3%
H
288
323.0
|
L
 12.5%
H
269.8
323.0
|
L
 -0.5%
H
253.3
335.9
|
L
 15.6%
H
211.7
346.9
|
L
 38.2%
H
198.6
346.9
|
L
 99.6%
H
133.6
346.9
|
| Amylyx Pharmaceuticals Inc |
|
1,351.9
|
12.3
|
L
 -1.2%
H
11.9
12.6
|
L
 -11.6%
H
11.9
14.0
|
L
 -8.8%
H
11.9
17.0
|
L
 57.0%
H
7.5
17.0
|
L
 88.2%
H
2.6
17.0
|
L
 -62.5%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharmaceuticals Inc |
|
1,145.7
|
24.0
|
L
 -0.8%
H
23.7
27.4
|
L
 -5.8%
H
23.7
27.4
|
L
 -7.0%
H
22.9
27.4
|
L
 11.2%
H
22.1
31.3
|
L
 -47.9%
H
20.4
49.5
|
L
 -20.2%
H
20.4
67.7
|
L
 25.2%
H
16.9
67.7
|
L
 86.0%
H
10.5
67.7
|
| AnaptysBio Inc |
|
1,097.8
|
39.7
|
L
 3.8%
H
36.4
39.8
|
L
 8.4%
H
34.2
41.0
|
L
 32.7%
H
30.3
41.0
|
L
 94.7%
H
17.1
41.0
|
L
 84.5%
H
12.2
41.0
|
L
 36.3%
H
12.2
41.3
|
L
 37.2%
H
12.2
41.3
|
L
H
10
134
|
| Anebulo Pharmaceuticals Inc |
|
99.4
|
2.4
|
L
 -3.2%
H
2.3
2.5
|
L
 -8.3%
H
2.3
2.7
|
L
 4.8%
H
2.3
2.9
|
L
 0.8%
H
1.8
2.9
|
L
 64.6%
H
0.8
3.4
|
L
 -12%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| ANI Pharmaceuticals Inc |
|
2,015.8
|
90.4
|
L
 0.2%
H
79.4
95.5
|
L
 -0.2%
H
79.4
95.6
|
L
 -1.4%
H
79.4
97
|
L
 31.0%
H
77.0
99.5
|
L
 54.9%
H
52.5
99.5
|
L
 136.5%
H
32.2
99.5
|
L
 281.7%
H
22.3
99.5
|
L
 111.9%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
137.9
|
4.2
|
L
 3.2%
H
3.9
4.2
|
L
 1.5%
H
3.8
4.2
|
L
 2.0%
H
3.8
5.0
|
L
 39.2%
H
2.9
5.0
|
L
 15.8%
H
2.1
5.0
|
L
 -21.2%
H
2.1
6.5
|
L
 105.4%
H
1.9
8.1
|
L
 31.8%
H
0.6
8.1
|
| Annexon Inc |
|
316.5
|
2.9
|
L
 -4.6%
H
2.7
3.0
|
L
 -8.9%
H
2.7
3.4
|
L
 -6.2%
H
2.7
3.6
|
L
 21.5%
H
2.0
3.6
|
L
 -62.0%
H
1.3
7.4
|
L
 -43.4%
H
1.3
8.4
|
L
 -87.7%
H
1.3
38.0
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
31.2
|
1.1
|
L
 1.8%
H
1.1
1.2
|
L
 -7.3%
H
1.1
1.2
|
L
 -13.0%
H
1.1
1.4
|
L
 5.6%
H
1.1
1.4
|
L
 3.6%
H
1.0
1.7
|
L
 -93.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
15.4
|
3.5
|
L
 0.9%
H
3.4
3.6
|
L
 2.6%
H
3.3
3.6
|
L
 -23.9%
H
3.3
6.2
|
L
 -16.3%
H
2.1
7.2
|
L
 -97.6%
H
0.7
190.8
|
L
 -100.0%
H
0.7
28875
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2784000
|
| Apollomics Inc Ordinary |
|
30.4
|
14.2
|
L
 6.5%
H
12.5
15.0
|
L
 1.5%
H
11.3
15.8
|
L
 -23.1%
H
10.0
42.1
|
L
 154.1%
H
3.7
42.1
|
L
 11.6%
H
0.1
42.1
|
L
 -98.6%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharmaceuticals Inc |
|
2,436.9
|
19.3
|
L
 -2.3%
H
18.8
19.7
|
L
 -10.3%
H
18.8
21.4
|
L
 -23.6%
H
18.8
30.5
|
L
 -20.8%
H
18.8
30.5
|
L
 -33.0%
H
16.1
35.7
|
L
 -59.6%
H
16.1
94.8
|
L
 -46.5%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
122.4
|
0.9
|
L
 13.3%
H
0.8
0.9
|
L
 -26.1%
H
0.8
1.2
|
L
 -20.6%
H
0.8
1.5
|
L
 97.7%
H
0.4
1.5
|
L
 -91.1%
H
0.3
10.6
|
L
 18.1%
H
0.3
10.6
|
L
 -94.8%
H
0.3
29.8
|
L
H
0.3
57.4
|
| Aptorum Group Ordinary |
|
11.2
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 -4.2%
H
1.3
1.5
|
L
 -34.0%
H
1.3
2.6
|
L
 7.0%
H
1.2
4.5
|
L
 7.8%
H
0.5
7.5
|
L
 -77.6%
H
0.5
17.5
|
L
 -93.2%
H
0.5
49.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
7.2
|
1.2
|
L
 2.5%
H
1.2
1.3
|
L
 -12.1%
H
1.2
1.5
|
L
 -14.6%
H
1.2
1.7
|
L
 -25.5%
H
1.2
1.8
|
L
 -69.1%
H
1.2
5
|
L
 -90.3%
H
1.2
13.2
|
L
 -99.7%
H
1.2
619.8
|
L
H
1.2
1062.2
|
| Aptevo Therapeutics Inc |
|
20.3
|
1.5
|
L
H
1.4
1.5
|
L
 -5.2%
H
1.4
1.5
|
L
 -16.5%
H
1.4
1.8
|
L
 -31.3%
H
1.3
2.7
|
L
 -99.4%
H
1.3
298
|
L
 -100.0%
H
1.3
234432
|
L
 -100.0%
H
1.3
1953600
|
L
H
1.3
3778913.6
|
| AquaBounty Technologies Inc |
|
4.1
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -19.2%
H
1.0
1.3
|
L
 -50%
H
1.0
2.1
|
L
 41.9%
H
0.7
3.0
|
L
 -4.6%
H
0.5
3.0
|
L
 -91.9%
H
0.5
23.6
|
L
 -98.7%
H
0.5
266.4
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
667.9
|
6.0
|
L
 -1.5%
H
5.8
6.4
|
L
 -11.4%
H
5.8
6.9
|
L
 1.2%
H
5.8
7.6
|
L
 53.7%
H
3.7
7.6
|
L
 18.9%
H
2.1
7.6
|
L
 563.7%
H
0.7
7.6
|
L
 7.3%
H
0.6
8.1
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings |
|
236.8
|
8.7
|
L
 5.2%
H
7.9
8.8
|
L
 -12.5%
H
7.9
10.1
|
L
 -57.4%
H
7.9
24.2
|
L
 -27.2%
H
7.9
24.2
|
L
 -53.5%
H
7.9
24.2
|
L
 -62.0%
H
7.9
45
|
L
 -86.2%
H
7.9
129.7
|
L
 -84.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,358.2
|
5.6
|
L
 -1.1%
H
5.4
5.7
|
L
 -7.8%
H
5.4
6.4
|
L
 8.1%
H
4.7
6.7
|
L
 8.8%
H
4.7
6.8
|
L
 -12.4%
H
3.2
6.8
|
L
 299.3%
H
1.2
10.1
|
L
 4.3%
H
0.5
10.1
|
L
 -70.8%
H
0.5
21.0
|
| Arcutis Biotherapeutics Inc |
|
2,968.0
|
24.2
|
L
 -3.5%
H
23.3
25.1
|
L
 -4.3%
H
23.3
25.4
|
L
 17.8%
H
19.6
27.1
|
L
 71.6%
H
13.7
27.1
|
L
 133.0%
H
8.9
27.1
|
L
 30.9%
H
1.8
27.1
|
L
 32.8%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.4
|
2.2
|
L
 17.8%
H
1.8
2.2
|
L
 -29.7%
H
1.7
3.2
|
L
 -50%
H
1.7
5.0
|
L
 -75.9%
H
1.7
10.6
|
L
 -70.0%
H
1.7
28.6
|
L
 -86.7%
H
1.7
28.6
|
L
 -95.7%
H
1.7
330.3
|
L
H
1.7
15552
|
| Arvinas Inc |
|
752.8
|
10.6
|
L
 6.3%
H
9.8
10.7
|
L
 4.8%
H
9.3
10.7
|
L
 14.3%
H
8.8
10.7
|
L
 70.4%
H
6.1
10.7
|
L
 -61.7%
H
5.9
28.7
|
L
 -75.0%
H
5.9
58.0
|
L
 -51.6%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharmaceuticals Inc |
|
5,423.8
|
39.2
|
L
 -0.9%
H
37.4
39.3
|
L
 -7.5%
H
37.4
43.2
|
L
 7.4%
H
34.6
43.7
|
L
 144.3%
H
15.0
43.7
|
L
 83.4%
H
9.6
43.7
|
L
 14.3%
H
9.6
43.7
|
L
 -41.0%
H
9.6
93.7
|
L
 633.3%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
485.5
|
31.2
|
L
 0.0%
H
30.6
31.8
|
L
 0.5%
H
30
32.7
|
L
 30.8%
H
23.2
32.7
|
L
 47.0%
H
20.2
32.7
|
L
 78.3%
H
7.8
32.7
|
L
 75.7%
H
7.7
32.7
|
L
 -46.6%
H
7.7
84.2
|
L
 -71.4%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
995.2
|
9
|
L
 17.5%
H
7.4
9.4
|
L
 -11.2%
H
7.4
10.1
|
L
 1.1%
H
7.4
14.5
|
L
 -7.0%
H
7.4
14.5
|
L
 7.0%
H
3.7
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
73.1
|
0.8
|
L
H
0.7
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 -14.6%
H
0.7
0.9
|
L
 5.6%
H
0.7
1.0
|
L
 -24.8%
H
0.5
1.1
|
L
 -71.6%
H
0.5
8.0
|
L
 -60.4%
H
0.5
8.0
|
L
 -99.0%
H
0.5
108.1
|
| ATAI Life Sciences NV |
|
1,583.2
|
4.4
|
L
 0.5%
H
4.2
4.4
|
L
 -25.3%
H
4.1
5.9
|
L
 -21.3%
H
4.1
6.8
|
L
 5.1%
H
3.6
6.8
|
L
 223.0%
H
1.2
6.8
|
L
 50.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| Athira Pharma Inc |
|
15.2
|
3.9
|
L
 -4.0%
H
3.7
4.1
|
L
 -7.5%
H
3.7
4.5
|
L
 -0.3%
H
3.6
4.5
|
L
 4.1%
H
3.5
4.6
|
L
 -46.8%
H
2.2
8.3
|
L
 -87.3%
H
2.2
44.1
|
L
 -98.3%
H
2.2
347.9
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
286.6
|
17.9
|
L
 12.3%
H
15.4
18.0
|
L
 -8.7%
H
15.3
19.5
|
L
 -23%
H
14.5
24.4
|
L
 -47.7%
H
14.5
174.6
|
L
 -39.5%
H
6.6
174.6
|
L
 -98.8%
H
6.6
2124.2
|
L
 -99.9%
H
6.6
49571
|
L
H
6.6
49571
|
| Atossa Therapeutics Inc |
|
105.9
|
0.8
|
L
H
0.8
0.8
|
L
 -7.9%
H
0.8
0.9
|
L
 -18.8%
H
0.8
1.3
|
L
 6.5%
H
0.7
1.3
|
L
 -45.3%
H
0.6
1.7
|
L
 -3.5%
H
0.5
2.3
|
L
 -47.4%
H
0.5
9.8
|
L
 -99.3%
H
0.5
135
|
| Atara Biotherapeutics Inc |
|
82.9
|
11.8
|
L
 -0.1%
H
10.5
12.0
|
L
 -20.5%
H
10.5
15.3
|
L
 -24.4%
H
10.5
16.7
|
L
 7.8%
H
10.3
16.7
|
L
 16.9%
H
5
18.7
|
L
 -90.0%
H
0.4
141
|
L
 -96.5%
H
0.4
705
|
L
 -98.6%
H
0.4
1361.3
|
| Astria Therapeutics Inc |
|
706.0
|
12.5
|
L
 0.6%
H
12.2
12.5
|
L
 -1.0%
H
12.1
12.7
|
L
 67.5%
H
7.6
12.7
|
L
 87.6%
H
6.1
12.7
|
L
 6.3%
H
3.6
12.7
|
L
 49.3%
H
3.6
16.9
|
L
 58.0%
H
2.4
47.8
|
L
 -97.2%
H
2.4
649.8
|
| Aurinia Pharmaceuticals Inc |
|
1,926.2
|
14.6
|
L
 4.7%
H
14.5
15.3
|
L
 10.9%
H
12.8
16.2
|
L
 24.8%
H
10.9
16.2
|
L
 27.8%
H
10.3
16.2
|
L
 75.2%
H
6.6
16.2
|
L
 189.3%
H
4.1
16.2
|
L
 6.1%
H
4.1
34.0
|
L
 393.6%
H
1.4
34.0
|
| Aura Biosciences Inc |
|
332.3
|
5.4
|
L
 -1.1%
H
5.2
5.4
|
L
 -12.7%
H
5.2
6.2
|
L
 -7.1%
H
5.2
6.6
|
L
 -18.3%
H
5.2
7.4
|
L
 -52.1%
H
4.3
11.2
|
L
 -56.0%
H
4.3
14.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharmaceuticals Inc |
|
259.5
|
3.3
|
L
 0.6%
H
3.2
3.3
|
L
 0.6%
H
3.2
3.3
|
L
 10.1%
H
3.0
3.3
|
L
 -5.5%
H
2.8
3.9
|
L
 -6.8%
H
2.5
4.0
|
L
 -44.3%
H
2.5
6.1
|
L
 -90.4%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
361.5
|
19.3
|
L
 1.7%
H
17.7
20.2
|
L
 5.9%
H
15.5
20.7
|
L
 29.6%
H
14.8
26
|
L
 -11.9%
H
14.4
27.3
|
L
 -57.4%
H
13.7
61.1
|
L
 143.9%
H
1.4
61.1
|
L
 -89.0%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
422.7
|
9.2
|
L
 2.7%
H
8.4
9.3
|
L
 -6.2%
H
8.4
10.0
|
L
 1.7%
H
8.4
10.5
|
L
 25.6%
H
6.7
10.5
|
L
 -90.4%
H
6.6
100.1
|
L
 -98.5%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
267.9
|
15.1
|
L
 -2.4%
H
14.2
15.6
|
L
 -16.5%
H
14.2
18.7
|
L
 11.7%
H
13.2
19.4
|
L
 80.2%
H
8.3
19.4
|
L
 16.6%
H
3.4
19.4
|
L
 124.6%
H
0.0
34.5
|
L
 -39.1%
H
0.0
54
|
L
H
0.0
91.8
|
| Anavex Life Sciences |
|
626.2
|
7.3
|
L
 -1.5%
H
7.1
7.5
|
L
 -8.5%
H
7.1
7.9
|
L
 -25.5%
H
7.1
10.1
|
L
 -35.0%
H
7.1
11.7
|
L
 -4.6%
H
7.1
14.4
|
L
 -36.6%
H
3.3
15.2
|
L
 48.5%
H
3.3
31.5
|
L
 -11.1%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
6,964.5
|
138.2
|
L
 -0.9%
H
134.5
139.5
|
L
 2.3%
H
123.5
141.4
|
L
 16.4%
H
117.3
141.4
|
L
 32.4%
H
102.7
141.4
|
L
 52.3%
H
75.6
141.4
|
L
 143.1%
H
49.6
141.4
|
L
 104.8%
H
19.4
141.4
|
L
H
1.9
141.4
|
| Aytu BioPharma Inc |
|
20.7
|
2.0
|
L
 -5.1%
H
2.0
2.1
|
L
 -10.6%
H
1.8
2.3
|
L
 -14.0%
H
1.8
2.6
|
L
 -14.4%
H
1.7
2.7
|
L
 11.5%
H
1.0
2.8
|
L
 -35.8%
H
1.0
4.9
|
L
 -99.0%
H
1.0
235.3
|
L
 -100.0%
H
1.0
4272000
|
| Aziyo Biologics Inc Ordinary |
|
-
|
0.9
|
L
 -4.3%
H
0.9
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 2.3%
H
0.9
1
|
L
 -54.6%
H
0.9
2.4
|
L
 -47.7%
H
0.9
2.6
|
L
 -89.1%
H
0.9
8.8
|
L
 -91.6%
H
0.9
18.2
|
L
H
0.9
18.2
|
| Adagene Inc ADR |
|
66.0
|
1.4
|
L
 -13.0%
H
1.3
1.7
|
L
 -21.4%
H
1.3
1.8
|
L
 -29.7%
H
1.3
2.1
|
L
 -35.8%
H
1.3
3.2
|
L
 -54.6%
H
1.3
3.2
|
L
 48.9%
H
0.9
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics ADR |
|
7.9
|
8.5
|
L
 -3.0%
H
8.5
9.0
|
L
 -6.7%
H
8.5
9.5
|
L
 -2.1%
H
8.5
12.0
|
L
 4.3%
H
7.5
12.1
|
L
 -20.1%
H
6.5
12.1
|
L
 -42.7%
H
5
45.6
|
L
 -96.2%
H
5
700
|
L
H
5
750.4
|
| Akari Therapeutics Plc ADR |
|
20.9
|
0.6
|
L
 3.2%
H
0.6
0.7
|
L
 -14.7%
H
0.6
0.8
|
L
 -39.1%
H
0.6
1.1
|
L
 -36.6%
H
0.6
1.2
|
L
 -73.7%
H
0.6
2.6
|
L
 -93.5%
H
0.6
12.6
|
L
 -98.1%
H
0.6
84.2
|
L
 -99.8%
H
0.6
444
|
| Amarin Corp ADR |
|
326.7
|
15.7
|
L
 0.3%
H
15.1
15.8
|
L
 -3.6%
H
15.0
16.5
|
L
 -18.5%
H
15.0
20.9
|
L
 4.0%
H
14.5
20.9
|
L
 2608.6%
H
0.4
20.9
|
L
 1099.2%
H
0.4
20.9
|
L
 267.1%
H
0.4
20.9
|
L
 670.1%
H
0.4
26.1
|
| Argen X SE ADR |
|
52,619.9
|
854.7
|
L
 0.4%
H
838.9
857.5
|
L
 4.4%
H
809.1
857.5
|
L
 7.2%
H
749.8
857.5
|
L
 27.1%
H
631.5
857.5
|
L
 44.5%
H
510.1
857.5
|
L
 135.9%
H
327.7
857.5
|
L
 213.4%
H
246.0
857.5
|
L
H
17.3
857.5
|
| Ascendis Pharma AS ADR |
|
11,974.0
|
197.7
|
L
 -0.8%
H
195.8
202.4
|
L
 -1.9%
H
195.0
209
|
L
 -5.8%
H
186.1
216.5
|
L
 3.9%
H
175.2
216.5
|
L
 56.3%
H
118.0
216.5
|
L
 58.5%
H
64.3
216.5
|
L
 17.0%
H
61.6
216.5
|
L
 1014.0%
H
11.9
216.5
|
| Alterity Therapeutics ADR |
|
62.7
|
3.5
|
L
 -1.1%
H
3.4
3.6
|
L
 -17.8%
H
3.4
4.1
|
L
 -19.2%
H
3.4
5.2
|
L
 -34.8%
H
3.4
5.6
|
L
 193.2%
H
1
7
|
L
 -7.5%
H
1
7
|
L
 -72.1%
H
1
35.8
|
L
 -93.2%
H
1
66.9
|
| Autolus Therapeutics plc ADR |
|
354.0
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 -14.2%
H
1.3
1.6
|
L
 -10.7%
H
1.3
1.8
|
L
 -43.4%
H
1.3
2.5
|
L
 -67.1%
H
1.1
4.1
|
L
 -41.9%
H
1.1
7.5
|
L
 -87.9%
H
1.1
12.3
|
L
H
1.1
53.2
|
| Avadel Pharmaceuticals plc |
|
1,825.2
|
18.7
|
L
 -0.1%
H
18.7
18.8
|
L
 -1.1%
H
18.7
19
|
L
 29.2%
H
13.8
19.1
|
L
 46.7%
H
12.4
19.1
|
L
 18.9%
H
6.4
19.1
|
L
 195.7%
H
5.6
19.1
|
L
 246.1%
H
1.1
19.1
|
L
 15.9%
H
1.0
19.1
|
| Astrazeneca plc ADR |
|
264,058.8
|
84.6
|
L
 1.0%
H
84.2
85.2
|
L
 2.7%
H
80.5
85.2
|
L
 -1.5%
H
80.5
86.5
|
L
 14.2%
H
72.9
86.6
|
L
 30.8%
H
61.2
86.6
|
L
 38.4%
H
60.5
87.7
|
L
 52.3%
H
46.5
87.7
|
L
 163.6%
H
25.6
87.7
|
| BridgeBio Pharma Inc |
|
11,909.4
|
61.8
|
L
 -1.5%
H
60.6
63.3
|
L
 -1.3%
H
60.2
64.4
|
L
 14.0%
H
52.8
69.5
|
L
 34.5%
H
45.4
69.5
|
L
 138.8%
H
21.7
69.5
|
L
 573.9%
H
6.6
69.5
|
L
 56.9%
H
5.0
73.5
|
L
H
5.0
73.5
|
| BioAtla Inc |
|
40.5
|
0.7
|
L
 7.8%
H
0.6
0.7
|
L
 -1.4%
H
0.6
0.7
|
L
 -13.8%
H
0.6
1.1
|
L
 81.6%
H
0.3
1.1
|
L
 -68.1%
H
0.2
2.5
|
L
 -91.4%
H
0.2
11.7
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
13.8
|
1.3
|
L
 1.6%
H
1.3
1.3
|
L
 -7.1%
H
1.3
1.5
|
L
 -1.5%
H
1.3
1.6
|
L
 -22.6%
H
1
2.3
|
L
 -45.2%
H
1
3.2
|
L
 -95.4%
H
1
43.8
|
L
 -95.5%
H
1
129
|
L
 -98.9%
H
1
2073.6
|
| Biocryst Pharmaceuticals Inc |
|
1,492.8
|
7.1
|
L
 0.9%
H
6.8
7.1
|
L
 -3.1%
H
6.5
7.3
|
L
 2.0%
H
6
7.5
|
L
 -15.1%
H
6
8.7
|
L
 -7.6%
H
6
11.3
|
L
 -40.1%
H
4.0
14.2
|
L
 73.8%
H
3.8
20.0
|
L
 -22.6%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
21.3
|
11.3
|
L
 15.1%
H
9.9
11.6
|
L
 2.8%
H
9.7
11.6
|
L
 -10.4%
H
9.7
14.7
|
L
 -83.5%
H
7.3
79
|
L
 -98.9%
H
7.3
1905
|
L
 -99.9%
H
7.3
12033
|
L
 -99.8%
H
7.3
18526.5
|
L
 -100.0%
H
7.3
138373.2
|
| Black Diamond Therapeutics Inc |
|
221.5
|
3.9
|
L
 -2.3%
H
3.8
4.0
|
L
 0.5%
H
3.6
4.2
|
L
 -0.5%
H
3.6
4.5
|
L
 70.6%
H
2.3
4.5
|
L
 22.3%
H
1.2
4.5
|
L
 76.0%
H
1.2
7.7
|
L
 -88.0%
H
1.2
37.8
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,253.8
|
22.2
|
L
 -4.1%
H
21.2
22.6
|
L
 -11.2%
H
21.2
25.2
|
L
 -11.6%
H
21.2
31.5
|
L
 24.4%
H
15.6
31.5
|
L
 -14.9%
H
13.5
35.3
|
L
 -41.4%
H
13.5
54.3
|
L
 -38.5%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
11.5
|
1.1
|
L
 -6.9%
H
1.0
1.1
|
L
 -1.8%
H
1.0
1.2
|
L
 3.9%
H
0.9
1.2
|
L
 13.7%
H
0.8
1.2
|
L
 22.7%
H
0.5
1.9
|
L
 -94.6%
H
0.5
22.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
22,813.7
|
155.5
|
L
 -0.8%
H
151.8
156.7
|
L
 0.8%
H
148.5
157.8
|
L
 2.2%
H
138
157.8
|
L
 21.7%
H
127
160.2
|
L
 -10.6%
H
110.0
175.9
|
L
 -45.4%
H
110.0
319.8
|
L
 -52.7%
H
110.0
468.6
|
L
 -42.8%
H
110.0
468.6
|
| BioVie Inc |
|
11.2
|
1.5
|
L
 -1.3%
H
1.4
1.5
|
L
 -15.4%
H
1.4
1.8
|
L
 -26.4%
H
1.4
2.1
|
L
 -49.1%
H
1.4
2.1
|
L
 -94.4%
H
1.4
38.5
|
L
 -99.6%
H
1.4
1438
|
L
 -99.8%
H
1.4
4609.8
|
L
 -99.9%
H
1.4
5625
|
| Biomea Fusion Inc |
|
96.9
|
1.4
|
L
 5.4%
H
1.2
1.4
|
L
 0.7%
H
1.2
1.4
|
L
 -25.5%
H
1.2
1.9
|
L
 -16.0%
H
1.2
3.0
|
L
 -83.3%
H
1.2
8.5
|
L
 -86.4%
H
1.2
43.7
|
L
H
1.2
43.7
|
L
H
1.2
43.7
|
| Biomarin Pharmaceutical Inc |
|
9,886.2
|
51.5
|
L
 -0.7%
H
50.8
51.9
|
L
 -3.9%
H
50.8
54.3
|
L
 -5.9%
H
50.8
56.8
|
L
 -13.5%
H
50.8
60.1
|
L
 -23.1%
H
50.8
73.5
|
L
 -36.7%
H
50.8
117.8
|
L
 -32.9%
H
50.8
117.8
|
L
 -55.2%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
15.8
|
1.6
|
L
 1.2%
H
1.5
1.6
|
L
 -9.4%
H
1.5
1.8
|
L
 -18.9%
H
1.5
2.2
|
L
 -44.4%
H
1.5
5.5
|
L
 443.3%
H
0.1
11.6
|
L
 -92.7%
H
0.1
30.1
|
L
 -66.0%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
335.7
|
12.8
|
L
 6.6%
H
11.7
12.9
|
L
 -21.8%
H
11.5
16.3
|
L
 -7.2%
H
11.5
16.8
|
L
 8.9%
H
11.1
16.8
|
L
 18.9%
H
9.1
17.2
|
L
 370.2%
H
1.9
17.2
|
L
 -72.0%
H
1.9
178.3
|
L
 -99.1%
H
1.9
1482.4
|
| Bolt Biotherapeutics Inc |
|
8.7
|
4.6
|
L
 -4.8%
H
4.4
4.8
|
L
 -21.0%
H
4.4
5.9
|
L
 -26.6%
H
4.4
6.6
|
L
 -19.3%
H
4.4
6.6
|
L
 -65.1%
H
4.4
13.4
|
L
 -82.9%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Bon Natural Life |
|
14.9
|
1.8
|
L
 -2.1%
H
1.8
1.9
|
L
 -2.1%
H
1.8
2
|
L
 -10.3%
H
1.8
2.3
|
L
 43.0%
H
1.3
3.4
|
L
 -94.6%
H
1.1
73.8
|
L
 -99.4%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
36.0
|
1.8
|
L
 2.8%
H
1.7
1.9
|
L
 -10.7%
H
1.7
2
|
L
 -26.8%
H
1.7
2.9
|
L
 -46.3%
H
1.7
8.1
|
L
 173.1%
H
0.2
8.1
|
L
 -84.3%
H
0.2
34.1
|
L
 -96.6%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
48.8
|
2.7
|
L
 2.6%
H
2.7
2.9
|
L
 -19.2%
H
2.7
3.3
|
L
 -18.7%
H
2.7
4.2
|
L
 2.6%
H
2.5
4.2
|
L
 3325%
H
0.1
5.9
|
L
 142.5%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
79.0
|
2.0
|
L
 2.1%
H
1.9
2.2
|
L
 -1.5%
H
1.9
2.3
|
L
 8.9%
H
1.6
2.4
|
L
 -3.9%
H
1.6
2.4
|
L
 4.8%
H
1.0
3.4
|
L
 172.2%
H
0.5
4
|
L
 -87.8%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics Plc ADR |
|
446.7
|
6.4
|
L
 -1.1%
H
6.2
6.5
|
L
 -20.2%
H
6.1
8.1
|
L
 -19.5%
H
6.1
9.2
|
L
 -13.7%
H
6.1
9.2
|
L
 -74.5%
H
6.1
25.4
|
L
 -72.5%
H
6.1
33.5
|
L
 -65.2%
H
6.1
62.1
|
L
H
6.1
62.1
|
| Biodexa Pharmaceuticals Plc |
|
3.3
|
5.4
|
L
 2.1%
H
5.1
5.5
|
L
 -14.7%
H
5
6.2
|
L
 -34.8%
H
5
11.9
|
L
 -20.6%
H
5
11.9
|
L
 -90.1%
H
5
92
|
L
 -100.0%
H
5
4020000
|
L
 -100.0%
H
5
38295000
|
L
H
5
4045000000
|
| BeiGene ADR |
|
34,085.2
|
320.0
|
L
 -3.7%
H
312.9
320.6
|
L
 3.1%
H
306.6
343.8
|
L
 -6.3%
H
306
353
|
L
 7.3%
H
280.1
355.3
|
L
 54.7%
H
171.0
355.3
|
L
 66.0%
H
127.0
355.3
|
L
 9.0%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx ADR |
|
13.9
|
3.3
|
L
 -1.8%
H
3.1
3.4
|
L
 -5.8%
H
3.1
3.6
|
L
 -26.4%
H
3.1
4.5
|
L
 -10.4%
H
3.1
4.6
|
L
 -81.9%
H
0.1
22.6
|
L
 -90.2%
H
0.1
101.2
|
L
 -96.9%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc ADR |
|
3,949.3
|
113.2
|
L
 1.3%
H
106.1
117.9
|
L
 6.9%
H
106.1
117.9
|
L
 46.2%
H
76.5
117.9
|
L
 61.5%
H
60
117.9
|
L
 37.4%
H
49
117.9
|
L
 314.9%
H
11
117.9
|
L
H
6
117.9
|
L
H
6
117.9
|
| Neuphoria Therapeutics Inc |
|
9.7
|
4.1
|
L
 -4.2%
H
4.1
4.4
|
L
 -9.9%
H
3.9
4.6
|
L
 -78.2%
H
3.8
19.6
|
L
 -47.1%
H
3.8
21.4
|
L
 979.0%
H
0.2
21.4
|
L
 -50.5%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE ADR |
|
24,800.6
|
103.1
|
L
 -0.2%
H
100.1
103.2
|
L
 -0.7%
H
100.1
109.0
|
L
 -2.8%
H
100.1
109.7
|
L
 -7.4%
H
90.1
114.9
|
L
 -4.4%
H
81.2
129.3
|
L
 -35.8%
H
76.5
189.0
|
L
 12.1%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharmaceuticals ADR |
|
-
|
1.0
|
L
 -3.8%
H
1
1.1
|
L
 -27.1%
H
1
1.6
|
L
 -30.1%
H
1
1.6
|
L
 -33.8%
H
1
2.0
|
L
 -65.0%
H
1
6.2
|
L
 -87.7%
H
0.6
99
|
L
 -96.2%
H
0.6
99
|
L
 -97.5%
H
0.6
620
|
| Cabaletta Bio Inc |
|
233.2
|
2.6
|
L
 2.8%
H
2.3
2.6
|
L
 -29.4%
H
2.3
3.6
|
L
 9.9%
H
2.2
3.7
|
L
 75.9%
H
1.3
3.7
|
L
 -44.3%
H
1.0
5.5
|
L
 17.0%
H
1.0
26.4
|
L
 -80.8%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
42.5
|
3.0
|
L
 -0.7%
H
3.0
3.1
|
L
 2.7%
H
3.0
3.1
|
L
 -10.3%
H
3.0
3.7
|
L
 4.5%
H
2.3
3.7
|
L
 -13.1%
H
1.4
4.3
|
L
 -78.5%
H
1
14.6
|
L
 -98.9%
H
1
530.3
|
L
H
1
530.3
|
| Capricor Therapeutics Inc |
|
271.1
|
5.9
|
L
 -5.6%
H
5.9
6.3
|
L
 -8.9%
H
5.9
6.5
|
L
 -20.9%
H
5.9
7.8
|
L
 -26.5%
H
5.7
9.4
|
L
 -68.5%
H
5.7
20.8
|
L
 20.0%
H
2.7
23.4
|
L
 48.6%
H
2.6
23.4
|
L
 -85.9%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
37.7
|
4.0
|
L
 2.0%
H
3.9
4.2
|
L
 -13.6%
H
3.9
4.8
|
L
 -90.0%
H
3.9
43.7
|
L
 -82.6%
H
3.9
43.7
|
L
 -67.6%
H
3.9
43.7
|
L
 -98.8%
H
3.9
461.2
|
L
 -99.2%
H
3.9
1067.3
|
L
 -99.3%
H
3.9
1067.3
|
| CASI Pharmaceuticals Inc |
|
21.4
|
1.4
|
L
 3.8%
H
1.3
1.5
|
L
 -4.2%
H
1.3
1.5
|
L
 -25.8%
H
1.3
2.1
|
L
 -6.1%
H
1.2
3.1
|
L
 -75.4%
H
1.1
6.0
|
L
 -30.3%
H
1.1
8.5
|
L
 -92.8%
H
1.1
39
|
L
 -89.0%
H
1.1
88.9
|
| Crescent Biopharma Inc |
|
-
|
13.1
|
L
 0.2%
H
12.9
13.2
|
L
 3.0%
H
12
13.2
|
L
 16.3%
H
9.8
13.3
|
L
 19.4%
H
9.8
15.8
|
L
 15.7%
H
7.6
21.4
|
L
 158.5%
H
2.8
21.4
|
L
 -2.7%
H
0.9
21.4
|
L
 -89.8%
H
0.9
167.3
|
| C4 Therapeutics Inc |
|
226.8
|
2.3
|
L
 -1.7%
H
2.2
2.4
|
L
 -10.3%
H
2.2
2.7
|
L
 3.5%
H
2.0
2.8
|
L
 -9.3%
H
2.0
3.7
|
L
 -61.3%
H
1.1
6.2
|
L
 -73.6%
H
1.1
11.9
|
L
 -91.3%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Cidara Therapeutics Inc |
|
3,282.0
|
104.4
|
L
 5.8%
H
95.9
105
|
L
 -4.4%
H
95.7
109.4
|
L
 2.2%
H
93
121.2
|
L
 69.1%
H
56.5
121.2
|
L
 696.3%
H
12.9
121.2
|
L
 -53.4%
H
10
840
|
L
 -88.8%
H
10
1260
|
L
 -98.3%
H
10
7228
|
| Niagen Bioscience Inc |
|
545.9
|
6.8
|
L
 3.6%
H
6.6
6.9
|
L
 -9.3%
H
6.6
8.0
|
L
 -4.7%
H
6.6
8.0
|
L
 -28.8%
H
6.6
10.6
|
L
 1.0%
H
5.2
14.7
|
L
 216.7%
H
1.3
14.7
|
L
 52.3%
H
1.2
23.7
|
L
 52.7%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
424.7
|
7.2
|
L
 -2.2%
H
6.7
7.3
|
L
 -17.0%
H
6.7
8.8
|
L
 22.1%
H
5.9
9.2
|
L
 2.3%
H
5.7
9.2
|
L
 -53.9%
H
5.7
17.5
|
L
 -41.2%
H
5.7
30.2
|
L
H
5.7
59.9
|
L
H
5.7
59.9
|
| Compugen |
|
151.5
|
1.6
|
L
 -1.2%
H
1.5
1.6
|
L
 -8.5%
H
1.5
1.8
|
L
 -8.0%
H
1.5
2.4
|
L
 12.5%
H
1.3
2.4
|
L
 -10.5%
H
1.1
2.7
|
L
 88.4%
H
0.5
3.0
|
L
 -87.6%
H
0.5
15.2
|
L
 -76.2%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
146.5
|
1.7
|
L
H
1.6
1.7
|
L
 -7.3%
H
1.5
1.8
|
L
 -5.1%
H
1.5
2.1
|
L
 144.1%
H
0.7
3.8
|
L
 219.2%
H
0.2
3.8
|
L
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
155.7
|
1.3
|
L
 -10.1%
H
1.3
1.4
|
L
 -20.2%
H
1.3
1.7
|
L
 -21.6%
H
1.3
1.9
|
L
 52.3%
H
0.8
1.9
|
L
 63.4%
H
0.7
2.4
|
L
 -82.9%
H
0.7
11.0
|
L
 -92.0%
H
0.7
22.2
|
L
 -95.4%
H
0.7
32.0
|
| Cingulate Inc |
|
20.9
|
3.7
|
L
 1.4%
H
3.6
3.8
|
L
 -1.6%
H
3.6
3.9
|
L
 -10.1%
H
3.5
4.4
|
L
 -11.4%
H
3.5
4.4
|
L
 8.4%
H
3.3
6.0
|
L
 251.9%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
98.5
|
9.8
|
L
 5.7%
H
8.6
10.1
|
L
 -21.8%
H
8.6
13.5
|
L
 7.8%
H
7.7
13.5
|
L
 166.5%
H
3.5
13.5
|
L
 66.0%
H
2.3
13.5
|
L
 -49.5%
H
2.3
39.8
|
L
 1711.1%
H
0.5
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
10.8
|
3.4
|
L
 -1.2%
H
3.3
3.5
|
L
H
3.2
3.6
|
L
 -33.9%
H
3.2
5.2
|
L
 -28.0%
H
3.2
6.5
|
L
 -94.6%
H
3.2
66
|
L
 -93.9%
H
3.2
133.5
|
L
 -99.1%
H
3.2
894
|
L
 -100.0%
H
3.2
54000
|
| Clearside Biomedical Inc |
|
19.5
|
3.7
|
L
 -7.5%
H
3.7
4.0
|
L
 -8.6%
H
3.7
4.2
|
L
 -11%
H
3.6
4.5
|
L
 -35.2%
H
3.3
7.1
|
L
 -77.7%
H
3.3
17.4
|
L
 -83.1%
H
3.3
31.8
|
L
 -81.5%
H
3.3
116.0
|
L
H
3.3
376.2
|
| Clearmind Medicine Inc |
|
3.7
|
0.7
|
L
 -8.1%
H
0.6
0.7
|
L
 -15%
H
0.6
0.8
|
L
 -28.4%
H
0.6
1.2
|
L
 -33.3%
H
0.6
1.3
|
L
 -51.4%
H
0.6
2.2
|
L
 -91.4%
H
0.1
7.9
|
L
 -42.9%
H
0.1
21.9
|
L
H
0.1
21.9
|
| Compass Therapeutics Inc |
|
752.4
|
4.2
|
L
 5.8%
H
3.8
4.2
|
L
 13.1%
H
3.5
4.2
|
L
 17.2%
H
3.5
4.9
|
L
 52.2%
H
2.7
4.9
|
L
 129.9%
H
1.3
4.9
|
L
 9.6%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharmaceuticals Inc |
|
3.8
|
6.6
|
L
 -4.9%
H
6.6
6.8
|
L
 -14.7%
H
6.5
7.5
|
L
 -34.3%
H
6.5
10.6
|
L
 -6.0%
H
4.9
10.6
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
9900000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
102.9
|
1.1
|
L
 4.7%
H
1.0
1.1
|
L
 2.8%
H
1.0
1.2
|
L
 -0.9%
H
1.0
1.6
|
L
 60%
H
0.7
1.6
|
L
 -46.4%
H
0.5
2.1
|
L
 -4.3%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
15.2
|
1.1
|
L
 8.9%
H
1
1.1
|
L
 0.9%
H
1
1.1
|
L
 -9.1%
H
1
1.3
|
L
 -33.3%
H
1
2.7
|
L
 -35.3%
H
1
3.3
|
L
 -60%
H
1
3.3
|
L
 -89.4%
H
1
41.5
|
L
 -99.6%
H
1
331.2
|
| CoDiagnostics Inc |
|
24.7
|
0.4
|
L
 5.1%
H
0.4
0.4
|
L
 -10.9%
H
0.4
0.5
|
L
 7.9%
H
0.3
1.6
|
L
 64%
H
0.2
1.6
|
L
 -65.3%
H
0.2
1.6
|
L
 -88.5%
H
0.2
3.8
|
L
 -97.2%
H
0.2
20.7
|
L
H
0.2
31.0
|
| Coeptis Therapeutics Holdings |
|
66.1
|
13.7
|
L
 -1.7%
H
13
13.9
|
L
 -9.9%
H
13
15.5
|
L
 -17.9%
H
13
17
|
L
 29.3%
H
10.7
19.2
|
L
 231.2%
H
2.3
19.2
|
L
 -76.0%
H
2.3
60
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
2,070.4
|
14.8
|
L
 0.7%
H
13.9
15.1
|
L
 -9.1%
H
13.8
16.8
|
L
 -4.0%
H
13.8
17.2
|
L
 36.5%
H
10.7
17.2
|
L
 44.7%
H
3.7
17.2
|
L
 26.8%
H
3.7
17.2
|
L
 51.2%
H
3.7
18.1
|
L
H
1.2
70.6
|
| Collegium Pharmaceutical Inc |
|
1,668.3
|
42.3
|
L
 4.0%
H
40.6
43.1
|
L
 17.5%
H
35.2
43.1
|
L
 26.7%
H
31.3
43.1
|
L
 28.4%
H
31.3
43.1
|
L
 21.9%
H
23.2
43.1
|
L
 111.7%
H
18.9
43.1
|
L
 115.3%
H
14.0
43.1
|
L
 91.5%
H
7.4
43.1
|
| Corcept Therapeutics Inc |
|
7,754.5
|
73.7
|
L
 0.9%
H
71.5
74.0
|
L
 0.3%
H
67
77.0
|
L
 -18.4%
H
67
91
|
L
 3.1%
H
67
91
|
L
 35.8%
H
49
117.3
|
L
 196.8%
H
17.9
117.3
|
L
 307.5%
H
15.8
117.3
|
L
 1523.8%
H
3.2
117.3
|
| Cosmos Health Inc |
|
21.4
|
0.7
|
L
 3.0%
H
0.6
0.7
|
L
 -14.8%
H
0.6
0.8
|
L
 -33.0%
H
0.6
1.3
|
L
 -34.3%
H
0.6
1.3
|
L
 -1.4%
H
0.3
1.3
|
L
 -65.0%
H
0.3
23.8
|
L
 -99.4%
H
0.3
225
|
L
 -99.5%
H
0.3
312.5
|
| Cumberland Pharmaceuticals Inc |
|
31.9
|
2.1
|
L
 -2.7%
H
2.1
2.2
|
L
 -28.8%
H
2.1
3.0
|
L
 -40.2%
H
2.1
3.7
|
L
 -35.1%
H
2.1
3.7
|
L
 77.5%
H
1.0
7.3
|
L
 -7.4%
H
1.0
7.3
|
L
 -27.6%
H
1.0
7.5
|
L
 -66.3%
H
1.0
8.0
|
| Catalyst Pharmaceuticals Inc |
|
2,629.1
|
21.4
|
L
 1.9%
H
20.7
22.2
|
L
 0.6%
H
20.7
22.9
|
L
 2.7%
H
19.9
22.9
|
L
 8.9%
H
19.1
22.9
|
L
 -8%
H
19.1
26.6
|
L
 42.1%
H
11.1
26.6
|
L
 579.0%
H
3.2
26.6
|
L
 564.3%
H
0.5
26.6
|
| Corbus Pharmaceuticals |
|
178.8
|
10.5
|
L
 0.8%
H
9.9
10.6
|
L
 -13.4%
H
9.9
12.5
|
L
 -28.0%
H
9.9
20.6
|
L
 16.9%
H
8.4
20.6
|
L
 -43.2%
H
4.6
20.6
|
L
 169.7%
H
2.1
61.9
|
L
 -69.0%
H
2.1
120
|
L
 -79.1%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
194.6
|
2.1
|
L
 -2.3%
H
1.9
2.1
|
L
 -13.6%
H
1.9
3.5
|
L
 -14.0%
H
1.9
3.5
|
L
 15.5%
H
1.6
3.5
|
L
 -24.8%
H
0.7
3.5
|
L
 -76.9%
H
0.7
10.7
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc |
|
97.0
|
1.0
|
L
H
1.0
1.0
|
L
 -9.7%
H
1.0
1.2
|
L
 -3.8%
H
1.0
1.4
|
L
 -5.6%
H
0.9
1.4
|
L
 -50.7%
H
0.8
2.1
|
L
 78.9%
H
0.5
3.1
|
L
 -66.4%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
16.4
|
1.3
|
L
 -10.3%
H
1.2
1.4
|
L
 -12.1%
H
1.2
1.6
|
L
 -19.1%
H
1.2
1.7
|
L
 -23.8%
H
1.2
2.0
|
L
 -69.9%
H
1.0
4.7
|
L
 -91.6%
H
1.0
20
|
L
 -94.2%
H
1.0
348
|
L
 -99.5%
H
1.0
372
|
| CorMedix Inc |
|
843.0
|
10.8
|
L
 -0.2%
H
10.5
10.9
|
L
 -3.3%
H
10.5
11.7
|
L
 -3.0%
H
9.9
12.6
|
L
 -0.5%
H
9.8
15.0
|
L
 1.2%
H
5.6
17.4
|
L
 266.0%
H
2.6
17.4
|
L
 105.7%
H
2.6
18.8
|
L
 -22.3%
H
0.9
22.7
|
| Crinetics Pharmaceuticals Inc |
|
3,768.6
|
40
|
L
 -8.0%
H
38.8
41.1
|
L
 -8.1%
H
38.8
43.9
|
L
 -5.9%
H
38.8
46.1
|
L
 43.5%
H
25.8
47.4
|
L
 -33.1%
H
24.1
62.5
|
L
 130.3%
H
15.2
62.5
|
L
 216.0%
H
12.0
62.5
|
L
H
10.6
62.5
|
| Cronos Group Inc |
|
954.8
|
2.5
|
L
 0.4%
H
2.4
2.5
|
L
 -1.2%
H
2.4
2.6
|
L
 -5.3%
H
2.4
2.8
|
L
 9.3%
H
2.2
3.2
|
L
 20.4%
H
1.6
3.2
|
L
 -11.1%
H
1.6
3.6
|
L
 -67.0%
H
1.6
15.8
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,013.2
|
55.1
|
L
 -2.6%
H
52.4
55.2
|
L
 -13.9%
H
52.4
64.7
|
L
 -22.0%
H
52.4
78.5
|
L
 -1.5%
H
50.8
78.5
|
L
 6.3%
H
30.0
78.5
|
L
 10.9%
H
30.0
91.1
|
L
 -46.3%
H
30.0
220.2
|
L
H
11.6
220.2
|
| Corvus Pharmaceuticals Inc |
|
567.6
|
7.6
|
L
 -2.8%
H
7.0
7.8
|
L
 -5.5%
H
7.0
8.1
|
L
 10.6%
H
6.4
8.4
|
L
 84.0%
H
4.1
8.4
|
L
 -13.6%
H
2.5
10
|
L
 794.1%
H
0.6
10
|
L
 81.4%
H
0.6
10
|
L
H
0.6
22.1
|
| Champions Oncology Inc |
|
92.9
|
6.7
|
L
 -2.0%
H
6.7
6.8
|
L
 -1.5%
H
6.7
6.9
|
L
 3.1%
H
6.3
7
|
L
 10.3%
H
6.1
8.7
|
L
 56.0%
H
4.1
12.0
|
L
 2.0%
H
3.6
12.0
|
L
 -24.1%
H
3.6
14.7
|
L
 34.8%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
597.0
|
3.6
|
L
 -13.6%
H
3.4
3.9
|
L
 1.4%
H
3.4
4.6
|
L
 8.7%
H
3.1
4.6
|
L
 72.4%
H
1.7
4.6
|
L
 262%
H
0.4
4.6
|
L
 189.6%
H
0.4
5.9
|
L
 -48.4%
H
0.4
10.1
|
L
 -68.3%
H
0.4
35
|
| Cue Biopharma Inc |
|
53.8
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -9.1%
H
0.7
0.9
|
L
 -6.7%
H
0.7
1.0
|
L
 -13.6%
H
0.7
1.0
|
L
 -60.7%
H
0.5
2.0
|
L
 -78.7%
H
0.5
5.1
|
L
 -93.7%
H
0.5
18.4
|
L
H
0.5
31.7
|
| CureVac NV |
|
1,173.2
|
5.2
|
L
 -0.8%
H
5.2
5.3
|
L
 -2.4%
H
5.2
5.4
|
L
 -4.1%
H
5.2
5.4
|
L
 -4.6%
H
5.2
5.5
|
L
 82.8%
H
2.4
5.7
|
L
 -29.0%
H
2.2
12.8
|
L
 -89.7%
H
2.2
151.8
|
L
H
2.2
151.8
|
| Cadrenal Therapeutics Inc |
|
24.8
|
12.1
|
L
 -0.5%
H
11.8
12.7
|
L
 -11.1%
H
11.8
13.6
|
L
 -10.9%
H
11.8
14.5
|
L
 14.7%
H
10.2
14.6
|
L
 -25.5%
H
8.7
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Bio Green Med Solution Inc |
|
3.4
|
1.5
|
L
 2.7%
H
1.4
1.6
|
L
 -14.6%
H
1.3
2.0
|
L
 -67.8%
H
1.3
6.7
|
L
 -83.1%
H
1.3
10.1
|
L
 -98.5%
H
1.3
213.6
|
L
 -100.0%
H
1.3
4536
|
L
 -100.0%
H
1.3
41112
|
L
 -100.0%
H
1.3
907200
|
| Cyclerion Therapeutics Inc |
|
5.2
|
1.6
|
L
 -4.1%
H
1.6
1.7
|
L
 -13.4%
H
1.6
1.9
|
L
 -36.5%
H
1.6
2.6
|
L
 -31.4%
H
1.6
3.8
|
L
 -34.4%
H
1.3
8.4
|
L
 -81.9%
H
1.3
19.7
|
L
 -96.7%
H
1.3
138
|
L
H
1.3
457
|
| Cytokinetics Inc |
|
7,355.5
|
60.2
|
L
 -0.2%
H
58.3
60.4
|
L
 -5.4%
H
58.1
64.0
|
L
 0.0%
H
54.3
64.1
|
L
 70.7%
H
32.9
64.1
|
L
 7.7%
H
29.3
64.1
|
L
 64.8%
H
26.0
110
|
L
 255.1%
H
15.2
110
|
L
 456.0%
H
5.8
110
|
| Cellectis ADR |
|
320.0
|
3.2
|
L
 1.9%
H
3.2
3.3
|
L
 -7.5%
H
3.1
3.4
|
L
 -16.5%
H
3.1
5.5
|
L
 19.9%
H
2.5
5.5
|
L
 82.3%
H
1.1
5.5
|
L
 43.0%
H
1.0
5.5
|
L
 -81.3%
H
1.0
34.7
|
L
 -92.4%
H
1.0
42.2
|
| Chemomab Therapeutics ADR |
|
13.7
|
2.6
|
L
 2.3%
H
2.5
2.7
|
L
 -13.7%
H
2.5
3.1
|
L
 -24.1%
H
2.5
3.6
|
L
 -32.0%
H
2.4
4.1
|
L
 -55.4%
H
2.4
9.8
|
L
 -67.6%
H
1.7
21.4
|
L
 -96.6%
H
1.7
675.2
|
L
H
1.7
736
|
| Compass Pathways Plc ADR |
|
523.3
|
5.5
|
L
 -2.5%
H
5.3
5.6
|
L
 -13.8%
H
5.3
6.9
|
L
 -12.7%
H
5.3
7.1
|
L
 26.5%
H
4.0
7.1
|
L
 2.8%
H
2.3
7.1
|
L
 -41.8%
H
2.3
12.8
|
L
 -85.9%
H
2.3
61.7
|
L
H
2.3
61.7
|
| Centessa Pharmaceuticals plc |
|
2,974.0
|
22.1
|
L
 -3.2%
H
21.6
23.0
|
L
 -11.2%
H
17.1
25.4
|
L
 -4.3%
H
17.1
25.4
|
L
 28.8%
H
15.0
25.4
|
L
 37.1%
H
9.6
25.4
|
L
 517.9%
H
3
25.4
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
| Connect Biopharma Holdings |
|
86.4
|
1.6
|
L
 -6.6%
H
1.5
1.7
|
L
 -9.4%
H
1.5
1.7
|
L
 -12.9%
H
1.5
2.1
|
L
 -25.1%
H
1.2
2.5
|
L
 37.2%
H
0.5
2.9
|
L
 118.3%
H
0.5
2.9
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
24.7
|
1.8
|
L
 1.1%
H
1.8
2.0
|
L
 -6.6%
H
1.8
2.0
|
L
 -18.3%
H
1.8
2.3
|
L
 -10.3%
H
1.8
2.4
|
L
 -54.6%
H
1.8
9.2
|
L
 -83.6%
H
0.3
16.8
|
L
 -85.0%
H
0.3
46.2
|
L
 -99.6%
H
0.3
519.6
|
| Day One Biopharmaceuticals Inc |
|
999.0
|
9.7
|
L
 8.2%
H
9.0
10.0
|
L
 30.8%
H
7.1
10
|
L
 31.3%
H
6.9
10
|
L
 61.4%
H
5.9
10
|
L
 -38.3%
H
5.6
16.8
|
L
 -50.1%
H
5.6
25.8
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
239.7
|
9.1
|
L
 -0.9%
H
8.7
9.2
|
L
 12.2%
H
8.0
9.3
|
L
 20.7%
H
6.9
9.3
|
L
 24.8%
H
6.7
9.3
|
L
 59.5%
H
3.5
9.3
|
L
 312.2%
H
1.0
9.3
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharmaceuticals Inc |
|
-
|
6.9
|
L
 -5.1%
H
6.8
7.3
|
L
 -1.8%
H
6.8
7.8
|
L
 -18.9%
H
6.7
9.7
|
L
 -25.9%
H
6.7
11.3
|
L
 -21.2%
H
5.5
13.1
|
L
 -5.2%
H
4.1
14.4
|
L
 -88.6%
H
4.1
138.8
|
L
 -99.9%
H
4.1
29250
|
| DiaMedica Therapeutics Inc |
|
306.0
|
5.9
|
L
 -4.8%
H
5.8
6.4
|
L
 -16.2%
H
5.8
7.2
|
L
 -13.7%
H
5.8
7.2
|
L
 22.8%
H
4.4
7.5
|
L
 41.6%
H
3.2
7.5
|
L
 406.0%
H
1.1
7.5
|
L
 37.0%
H
1.1
10.9
|
L
 238.3%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
2,589.8
|
15.0
|
L
 4.2%
H
13.8
15.2
|
L
 -7.7%
H
13.8
16.3
|
L
 0.8%
H
13.8
17.7
|
L
 5.6%
H
12.6
17.7
|
L
 -49.3%
H
10.6
33.3
|
L
 -45.9%
H
10.6
33.3
|
L
 -72.3%
H
10.6
93.9
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
74.0
|
4.8
|
L
 2.6%
H
4.3
4.8
|
L
 -6.9%
H
4.3
5.1
|
L
 -27.1%
H
4.3
6.8
|
L
 -17.1%
H
4.3
8.4
|
L
 183.3%
H
0.8
13.6
|
L
 -7.9%
H
0.8
13.6
|
L
 -43.9%
H
0.8
43.4
|
L
 -98.8%
H
0.8
577.5
|
| DarioHealth Corp |
|
84.6
|
12.5
|
L
 3.5%
H
12
12.6
|
L
 -10.7%
H
12
14
|
L
 -19.6%
H
12
16.6
|
L
 19.1%
H
5.9
17.7
|
L
 -35.6%
H
5.9
31
|
L
 -84.5%
H
5.9
135.6
|
L
 -94.6%
H
5.9
637
|
L
 -99.5%
H
5.9
4669.9
|
| Dermata Therapeutics Inc |
|
2.1
|
3.0
|
L
 3.1%
H
2.9
3.1
|
L
 -11.1%
H
2.9
3.4
|
L
 -32.1%
H
2.9
5.2
|
L
 -52.3%
H
2.9
6.7
|
L
 126.9%
H
0.6
7.1
|
L
 -69.4%
H
0.2
12.2
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
416.7
|
58.8
|
L
 4.8%
H
55.5
59.3
|
L
 7.4%
H
50
59.3
|
L
 15.7%
H
49.8
70.2
|
L
 68.9%
H
34.2
70.2
|
L
 12.3%
H
23.2
70.2
|
L
 1124.8%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
| Design Therapeutics Inc |
|
430.6
|
7.6
|
L
 10.0%
H
6.8
7.9
|
L
 12.8%
H
6.2
7.9
|
L
 16.5%
H
5.3
7.9
|
L
 90.4%
H
4.0
7.9
|
L
 30.6%
H
2.6
7.9
|
L
 -49.6%
H
1.9
16.6
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
81.4
|
6.1
|
L
 -4.7%
H
6.1
6.3
|
L
 -24.8%
H
6.1
7.7
|
L
 8.1%
H
5.3
8.8
|
L
 34.4%
H
4.2
8.8
|
L
 -27.6%
H
3.6
8.8
|
L
 395.2%
H
0.3
19.4
|
L
 -8.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Technologies Corp |
|
1,271.7
|
10.8
|
L
 -1.5%
H
10.5
11.1
|
L
 5.6%
H
9.9
11.2
|
L
 6.8%
H
9.7
11.2
|
L
 -2.1%
H
9.2
12.1
|
L
 -9.9%
H
9.2
14.6
|
L
 -13.9%
H
9.2
15.2
|
L
 161.0%
H
3.8
21.4
|
L
 -56.2%
H
1.8
29.9
|
| Dyne Therapeutics Inc |
|
2,622.3
|
18.4
|
L
 0.9%
H
17.0
18.4
|
L
 -18.7%
H
17.0
24.3
|
L
 31.6%
H
13.7
25
|
L
 64.1%
H
10.8
25
|
L
 -37.3%
H
6.4
35.7
|
L
 85.6%
H
6.4
47.5
|
L
 -9.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Technologies ADR |
|
502.2
|
14.0
|
L
 -0.5%
H
13.2
15.0
|
L
 -4.6%
H
13.2
15.4
|
L
 -1.9%
H
13.2
18
|
L
 43.0%
H
8.7
18
|
L
 277.6%
H
0.5
18
|
L
 -6.9%
H
0.5
23.7
|
L
 -35.3%
H
0.5
73.8
|
L
 -96.2%
H
0.5
505.7
|
| Editas Medicine Inc |
|
222.1
|
2.5
|
L
 -8.2%
H
2.3
2.6
|
L
 -19.8%
H
2.3
3.1
|
L
 -37.2%
H
2.3
4.5
|
L
 -0.8%
H
2.1
4.5
|
L
 -22.1%
H
0.9
4.5
|
L
 -77.6%
H
0.9
13.9
|
L
 -91.9%
H
0.9
100.0
|
L
H
0.9
100.0
|
| Edesa Biotech Inc |
|
12.6
|
1.7
|
L
 0.6%
H
1.7
1.8
|
L
 -8.1%
H
1.7
2.0
|
L
 -37.8%
H
1.7
3.0
|
L
 -18.2%
H
1.7
3.0
|
L
 -33.7%
H
1.6
4.5
|
L
 -73.4%
H
1.6
19.7
|
L
 -95.7%
H
1.6
84
|
L
 -99.9%
H
1.6
2516.6
|
| Eledon Pharmaceuticals Inc |
|
123.4
|
2.1
|
L
 -49.8%
H
1.4
2.2
|
L
 -52.3%
H
1.4
4.6
|
L
 -24.5%
H
1.4
4.6
|
L
 -24.8%
H
1.4
4.6
|
L
 -59.0%
H
1.4
5.2
|
L
 -13.1%
H
1.1
5.4
|
L
 -89.9%
H
1.1
26.4
|
L
 -99.9%
H
1.1
2033.1
|
| Elicio Therapeutics Inc |
|
144.9
|
8.9
|
L
 -2.2%
H
8.6
9.5
|
L
 -4.5%
H
8.6
9.6
|
L
 -17.8%
H
8.6
11.2
|
L
 -2.2%
H
8.5
12.6
|
L
 92.4%
H
4.6
12.6
|
L
 -2.5%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,044.3
|
17.6
|
L
 -3.7%
H
16.8
18.4
|
L
 -24.7%
H
16.8
23.3
|
L
 -12.3%
H
16.8
24.6
|
L
 -1.5%
H
16.8
24.6
|
L
 -39.2%
H
13.3
29.4
|
L
 -1.2%
H
9.8
30.0
|
L
 -72.6%
H
3.9
119.7
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
124.0
|
1.8
|
L
 -6.2%
H
1.8
1.9
|
L
 -10.7%
H
1.8
2.1
|
L
 10.9%
H
1.7
2.5
|
L
 8.9%
H
1.5
2.6
|
L
 -50.5%
H
1.1
4.3
|
L
 -39%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics |
|
24.3
|
1
|
L
 -1.0%
H
1.0
1.0
|
L
 -4.8%
H
1.0
1.1
|
L
 -11.5%
H
1.0
1.2
|
L
 -25.9%
H
1.0
2.1
|
L
 -21.3%
H
0.8
2.1
|
L
 -75.9%
H
0.8
4.9
|
L
 -91.3%
H
0.8
29.4
|
L
 -99.5%
H
0.8
318
|
| Enochian Biosciences Inc |
|
-
|
0.9
|
L
 -8.8%
H
0.8
1.0
|
L
 6.9%
H
0.8
1.5
|
L
 -34.5%
H
0.8
1.5
|
L
 322.7%
H
0.1
1.5
|
L
 190.6%
H
0.1
1.5
|
L
 -48.6%
H
0.1
2.3
|
L
 -69.5%
H
0.1
13.8
|
L
 -78.1%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
6.1
|
2.1
|
L
 -0.5%
H
2.0
2.1
|
L
 -5.5%
H
2.0
2.2
|
L
 -14.9%
H
2.0
2.8
|
L
 -1.0%
H
2.0
2.8
|
L
 194.3%
H
0.4
9.9
|
L
 -92.8%
H
0.1
56.5
|
L
 -99.9%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Enanta Pharmaceuticals Inc |
|
317.1
|
11.0
|
L
 1.8%
H
10.2
11
|
L
 0.3%
H
10.2
11.3
|
L
 -0.8%
H
10.2
12.0
|
L
 57.2%
H
6.5
15.3
|
L
 -3.2%
H
4.1
15.3
|
L
 -74.2%
H
4.1
62.1
|
L
 -75.2%
H
4.1
102
|
L
 -66.5%
H
4.1
127.8
|
| Entera Bio |
|
143.4
|
3.1
|
L
 1.0%
H
3
3.2
|
L
 7.9%
H
2.5
3.2
|
L
 66.1%
H
1.9
3.2
|
L
 74.4%
H
1.8
3.2
|
L
 79.4%
H
1.5
3.2
|
L
 398.4%
H
0.5
3.4
|
L
 180.4%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
3.2
|
6.1
|
L
 1.2%
H
5.8
6.4
|
L
 7.2%
H
5.5
8.6
|
L
 -26.8%
H
5.5
11.4
|
L
 -54.1%
H
5.5
17.6
|
L
 -92.7%
H
5.5
93.6
|
L
 -98.9%
H
5.5
1256.4
|
L
 -100.0%
H
5.5
135360
|
L
 -100.0%
H
5.5
12150000
|
| Evolus Inc |
|
425.2
|
6.6
|
L
 -8.6%
H
6.5
7.3
|
L
 1.6%
H
6.2
7.8
|
L
 4.8%
H
5.9
7.8
|
L
 8.1%
H
5.7
8.0
|
L
 -54.1%
H
5.7
17.1
|
L
 -15.0%
H
5.7
17.8
|
L
 106.3%
H
3.1
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
39.3
|
1.1
|
L
 -12.7%
H
1.1
1.2
|
L
 -22.0%
H
1.1
1.6
|
L
 -26.2%
H
1.1
1.6
|
L
 100%
H
0.5
2.4
|
L
 42.9%
H
0.3
2.4
|
L
 -37.9%
H
0.3
3.3
|
L
 -75.3%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Erasca Inc |
|
643.9
|
2.3
|
L
 1.3%
H
2.1
2.3
|
L
 -6.2%
H
2.1
2.5
|
L
 -8.5%
H
2.1
2.8
|
L
 55.5%
H
1.3
2.8
|
L
 -27.0%
H
1.0
3.3
|
L
 -67.4%
H
1.0
9.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
630.6
|
2.7
|
L
 6.4%
H
2.5
2.7
|
L
 -10.4%
H
2.4
3
|
L
 -13.9%
H
2.3
3.1
|
L
 47.0%
H
1.7
3.4
|
L
 26.1%
H
0.7
3.9
|
L
 -68.0%
H
0.7
8.9
|
L
 -89.5%
H
0.7
39.5
|
L
 -90.4%
H
0.7
82.7
|
| Eton Pharmaceuticals Inc |
|
453.2
|
16.9
|
L
 -11.7%
H
16.3
19.4
|
L
 -6.2%
H
16.3
20.0
|
L
 -20.1%
H
16.3
21.9
|
L
 10.8%
H
14.7
23
|
L
 94.9%
H
8.4
23
|
L
 560.2%
H
2.4
23
|
L
 143.2%
H
2.0
23
|
L
H
2.0
23
|
| Evoke Pharma Inc |
|
16.7
|
10.7
|
L
 0.6%
H
10.6
10.7
|
L
 107.6%
H
4.5
10.8
|
L
 127.0%
H
4.4
10.8
|
L
 100.6%
H
4.2
10.8
|
L
 89.2%
H
1.9
10.8
|
L
 -47.0%
H
0.4
71.5
|
L
 -98.0%
H
0.4
691.2
|
L
 -98.0%
H
0.4
1599.8
|
| Edgewise Therapeutics Inc |
|
1,810.3
|
17.2
|
L
 0.4%
H
16.7
17.7
|
L
 -6.1%
H
16.7
18.6
|
L
 13.3%
H
14.3
18.8
|
L
 32.5%
H
12.3
18.8
|
L
 -51.6%
H
10.6
38.1
|
L
 78.9%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
10,941.7
|
40.8
|
L
 0.0%
H
39.9
40.8
|
L
 5.5%
H
36
41.5
|
L
 3.0%
H
33.8
41.5
|
L
 9.2%
H
33.8
41.8
|
L
 14.0%
H
31.9
49.6
|
L
 149.6%
H
15.3
49.6
|
L
 97.1%
H
14.9
49.6
|
L
 556.1%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
63.6
|
6.4
|
L
 13.6%
H
5.3
6.5
|
L
 -0.6%
H
5.3
6.5
|
L
 -31.1%
H
5.3
9.5
|
L
 17.1%
H
5.3
15
|
L
 -83.5%
H
0.0
41.1
|
L
 -95.9%
H
0.0
468
|
L
 -97.6%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharmaceuticals Inc |
|
928.0
|
11.2
|
L
 1.2%
H
10.3
11.2
|
L
 -14.4%
H
9.7
13.3
|
L
 -15.4%
H
9.7
14.4
|
L
 11.3%
H
9.7
14.9
|
L
 -3.3%
H
3.9
14.9
|
L
 114.3%
H
2.2
31.0
|
L
 201.3%
H
2.2
31.0
|
L
 -70.5%
H
2.2
58.1
|
| Evaxion Biotech AS ADR |
|
53.0
|
6.4
|
L
 1.9%
H
5.7
6.5
|
L
 11.0%
H
5.5
6.5
|
L
 11.5%
H
5.3
12.2
|
L
 117.8%
H
2.5
12.2
|
L
 143.5%
H
0.8
12.2
|
L
 -72.9%
H
0.8
24.4
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE ADR |
|
1,094.0
|
3.1
|
L
 -6.7%
H
3.0
3.1
|
L
 -24.3%
H
3.0
4.1
|
L
 -21.4%
H
3.0
4.3
|
L
 -20.2%
H
3.0
4.3
|
L
 -26.5%
H
2.8
5.6
|
L
 -67.6%
H
2.8
13.5
|
L
 -78.9%
H
2.8
26.6
|
L
 41.3%
H
1.6
26.6
|
| Fate Therapeutics Inc |
|
123.4
|
1.1
|
L
 2.9%
H
1
1.1
|
L
 -20.7%
H
1
1.4
|
L
 -23.0%
H
1
1.9
|
L
 9.2%
H
0.9
1.9
|
L
 -58.0%
H
0.7
3.5
|
L
 -94.6%
H
0.7
24.0
|
L
 -97.8%
H
0.7
121.2
|
L
 -77.7%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
77.7
|
2.6
|
L
 3.6%
H
2.5
2.6
|
L
 2.0%
H
2.4
2.6
|
L
 -14.4%
H
2.4
3.1
|
L
 41.1%
H
1.8
4.2
|
L
 51.7%
H
1.3
4.2
|
L
 -79.3%
H
1.2
17.4
|
L
 -92.5%
H
1.2
91.5
|
L
 -94.1%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
150.2
|
12.1
|
L
 5.6%
H
11.0
12.5
|
L
 -6.7%
H
10.3
13.5
|
L
 -15.1%
H
10.3
15.5
|
L
 17.3%
H
9.9
17
|
L
 151.1%
H
4.8
28
|
L
 -52.8%
H
4.1
32.3
|
L
 -98.6%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
578.4
|
10.5
|
L
 -3.9%
H
10.0
11.0
|
L
 -8.7%
H
10.0
11.8
|
L
 26.2%
H
8.3
12.3
|
L
 81.7%
H
5.3
12.3
|
L
 26.5%
H
2.2
12.3
|
L
 26.2%
H
2.2
36.3
|
L
H
2.2
55.1
|
L
H
2.2
55.1
|
| Fennec Pharmaceuticals Inc |
|
222.1
|
8.0
|
L
 -0.3%
H
7.9
8.1
|
L
 -2.7%
H
7.8
8.4
|
L
 -15.8%
H
7.8
9.7
|
L
 -1.1%
H
7.2
9.9
|
L
 83.0%
H
4.0
9.9
|
L
 -5.8%
H
4.0
11.9
|
L
 6.8%
H
3.8
11.9
|
L
 513.8%
H
0.3
15.0
|
| FibroGen Inc |
|
44.6
|
11.0
|
L
 0.3%
H
11
11.4
|
L
 -0.8%
H
11
11.4
|
L
 -0.4%
H
10.3
11.7
|
L
 38.9%
H
7.8
12.6
|
L
 41.1%
H
4.5
22.0
|
L
 -97.3%
H
4.5
642.3
|
L
 -98.9%
H
4.5
1430.2
|
L
 -98.3%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
246.6
|
4.4
|
L
 9%
H
3.9
4.4
|
L
 -1.1%
H
3.3
4.5
|
L
 -1.4%
H
3.3
4.7
|
L
 -12.5%
H
3.3
5.9
|
L
 -51.9%
H
2.9
9.7
|
L
 -51.9%
H
2.7
10.2
|
L
 -72.7%
H
2.7
28.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
27.6
|
2.3
|
L
 -2.6%
H
2.2
2.3
|
L
 -19.6%
H
2.2
2.9
|
L
 -10.3%
H
2.2
4.0
|
L
 26.3%
H
1.6
4.0
|
L
 -95.2%
H
1.3
48.7
|
L
 -91.3%
H
1.3
53.8
|
L
 -98.7%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Flora Growth Corp |
|
5.7
|
8.0
|
L
 -0.6%
H
7.3
8.3
|
L
 -16.0%
H
7.3
10.3
|
L
 -55.7%
H
7.3
20.5
|
L
 -54.0%
H
7.3
47
|
L
 -84.7%
H
7.3
81.9
|
L
 -98.0%
H
7.3
464.3
|
L
H
7.3
16731
|
L
H
7.3
16731
|
| Amicus Therapeutics Inc |
|
2,736.7
|
8.9
|
L
 -0.3%
H
8.7
9.0
|
L
 -1.8%
H
8.6
9.6
|
L
 8.7%
H
7.9
9.6
|
L
 30.6%
H
6.6
9.6
|
L
 -19.2%
H
5.5
11.4
|
L
 -14.0%
H
5.5
14.6
|
L
 -56.7%
H
5.5
25.4
|
L
 -16.9%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
33.8
|
L
 3.9%
H
30.2
34.3
|
L
 -17.3%
H
30.2
41.6
|
L
 -30.6%
H
30.2
55.9
|
L
 113.4%
H
14.2
55.9
|
L
 124.0%
H
10.3
55.9
|
L
 -70.1%
H
9.2
279.5
|
L
 -97.1%
H
9.2
2918.5
|
L
H
9.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
412.9
|
7.6
|
L
 -0.3%
H
7.3
7.7
|
L
 -12.8%
H
7.3
9.5
|
L
 -17.4%
H
7.3
10.1
|
L
 12.0%
H
6.3
10.1
|
L
 119.3%
H
2.3
10.1
|
L
 36.0%
H
2.3
15
|
L
 -35.3%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
6.1
|
3.9
|
L
 12.7%
H
3.3
4.2
|
L
 -8.2%
H
3.3
4.3
|
L
 -5.3%
H
3.3
5.8
|
L
 900%
H
0.4
5.8
|
L
 828.6%
H
0.4
5.8
|
L
 -97.2%
H
0.4
179.2
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
335.3
|
5.2
|
L
 -6.8%
H
5.1
5.7
|
L
 -10.5%
H
5.1
6.3
|
L
 9.0%
H
4.6
6.3
|
L
 35.4%
H
3.5
6.6
|
L
 83.1%
H
0.7
6.6
|
L
 296.9%
H
0.7
6.6
|
L
 101.6%
H
0.7
6.6
|
L
 89.1%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
70.5
|
2.0
|
L
 3.2%
H
1.8
2.0
|
L
H
1.7
2.0
|
L
 -3.0%
H
1.7
2.2
|
L
 31.5%
H
1.5
2.4
|
L
 -12.1%
H
1.4
2.8
|
L
 -34.0%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| Generation Bio Co |
|
34.4
|
5.1
|
L
 1.8%
H
4.9
5.1
|
L
 -7.3%
H
4.9
5.5
|
L
 -18.0%
H
4.9
6.9
|
L
 23.1%
H
4.0
7.0
|
L
 -78.5%
H
3
25.2
|
L
 -92.1%
H
3
73.5
|
L
 -98.1%
H
3
557.2
|
L
H
3
557.2
|
| CytoMed Therapeutics |
|
22.1
|
1.9
|
L
 -7.8%
H
1.8
2.0
|
L
 -14.6%
H
1.7
3.1
|
L
 -13.0%
H
1.7
3.7
|
L
 1.1%
H
1.7
3.7
|
L
 -26.0%
H
1.7
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
| Geron Corp |
|
682.7
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -15.1%
H
1.0
1.3
|
L
 -17.1%
H
1.0
1.5
|
L
 -17.7%
H
1.0
1.6
|
L
 -75.1%
H
1.0
4.3
|
L
 -49.0%
H
1.0
5.3
|
L
 -39.5%
H
1.0
5.3
|
L
 -72.6%
H
0.8
7.0
|
| GH Research PLC |
|
837.4
|
13.5
|
L
 0.7%
H
12.4
13.7
|
L
 -5.7%
H
12.4
14.8
|
L
 3.1%
H
12.3
14.9
|
L
 11.6%
H
11.3
15.0
|
L
 56.6%
H
6.7
20.5
|
L
 43.3%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
147,718.1
|
118.8
|
L
 -3.7%
H
117.5
124
|
L
 -0.8%
H
117.5
124.1
|
L
 1.8%
H
114.0
124.6
|
L
 7.8%
H
108.5
124.6
|
L
 21.4%
H
86.1
124.6
|
L
 45.9%
H
62.1
124.6
|
L
 101.2%
H
56.6
124.6
|
L
 9.7%
H
56.6
124.6
|
| Galmed Pharmaceuticals |
|
6.6
|
1.2
|
L
 -2.4%
H
1.2
1.2
|
L
 -12.4%
H
1.2
1.4
|
L
 -24.1%
H
1.2
1.6
|
L
 -12.4%
H
1.2
1.7
|
L
 -61.0%
H
1.2
3.6
|
L
 -98.0%
H
0.2
170.1
|
L
 -99.8%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
120.0
|
8.7
|
L
 5.4%
H
7.9
8.9
|
L
 -6.0%
H
7.9
9.2
|
L
 -22.9%
H
7.9
11.5
|
L
 -25.8%
H
7.9
13
|
L
 -37.3%
H
7.9
15.5
|
L
 -3.6%
H
7.6
21.5
|
L
 123.2%
H
3.4
158.1
|
L
H
3.3
158.1
|
| Galecto Inc |
|
6.6
|
5.0
|
L
 -15.0%
H
5.0
5.5
|
L
 -32.4%
H
5.0
7.6
|
L
 -72.4%
H
5.0
18.5
|
L
 51.8%
H
2.5
31.7
|
L
 -31.8%
H
2.0
31.7
|
L
 142.6%
H
0.5
31.7
|
L
 -67.5%
H
0.5
31.7
|
L
H
0.5
31.7
|
| Monte Rosa Therapeutics Inc |
|
801.6
|
12.3
|
L
 -5.4%
H
11.9
13.4
|
L
 -4.2%
H
11.5
13.6
|
L
 66.8%
H
7.4
13.6
|
L
 191.0%
H
4.1
13.6
|
L
 29.2%
H
3.5
13.6
|
L
 49.0%
H
2.4
13.6
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
847.3
|
13.1
|
L
 0.2%
H
12.9
13.2
|
L
 3.0%
H
12
13.2
|
L
 16.3%
H
9.8
13.3
|
L
 19.4%
H
9.8
15.8
|
L
 -68.7%
H
9.8
44.8
|
L
 -80.7%
H
9.8
416
|
L
 -95.6%
H
9.8
440
|
L
 -98.1%
H
9.8
2605
|
| Genelux Corp |
|
204.7
|
5.4
|
L
 2.3%
H
5.3
5.8
|
L
 -32.9%
H
4.3
8.5
|
L
 15.1%
H
4.3
8.5
|
L
 62.3%
H
3.0
8.5
|
L
 86.3%
H
2.0
8.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
6.9
|
4.2
|
L
 -10.2%
H
4.2
4.8
|
L
 -27.0%
H
4.2
6.3
|
L
 2005%
H
0.2
13.0
|
L
 1813.6%
H
0.1
13.0
|
L
 149.1%
H
0.1
13.0
|
L
 226.4%
H
0.1
13.0
|
L
 34.1%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
546.2
|
2.4
|
L
 2.2%
H
2.2
2.4
|
L
 -3.7%
H
2.2
2.5
|
L
 -5.6%
H
2.1
2.6
|
L
 35.6%
H
1.7
3.6
|
L
 165.2%
H
0.7
3.6
|
L
 -76.5%
H
0.5
10.6
|
L
 -72.7%
H
0.5
15.2
|
L
H
0.5
27.2
|
| Geovax Labs Inc |
|
15.1
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -10.5%
H
0.5
0.6
|
L
 -7.3%
H
0.5
0.6
|
L
 -23.9%
H
0.5
0.8
|
L
 -73.4%
H
0.4
3.7
|
L
 -42.0%
H
0.3
11.1
|
L
 -81.9%
H
0.3
11.1
|
L
 -100.0%
H
0.3
1000000
|
| Graphite Bio Inc |
|
1,337.7
|
23.0
|
L
 0.0%
H
22.0
23.9
|
L
 -22.7%
H
21.2
29.6
|
L
 -51.1%
H
21.2
49.3
|
L
 -28.5%
H
21.2
50.4
|
L
 -14.3%
H
21.2
50.4
|
L
 -85.3%
H
21.2
413
|
L
H
21.2
1666
|
L
H
21.2
1666
|
| GT Biopharma Inc |
|
6.6
|
0.6
|
L
 12.7%
H
0.5
0.6
|
L
 -1.6%
H
0.5
0.7
|
L
 -17.3%
H
0.5
1.4
|
L
 -66.1%
H
0.5
1.9
|
L
 -80%
H
0.5
4.1
|
L
 -71.8%
H
0.2
10.7
|
L
 -79.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
30600
|
| Galapagos NV ADR |
|
2,074.7
|
31.5
|
L
 1.1%
H
31.0
32.0
|
L
 -0.8%
H
29.8
32.0
|
L
 -9.7%
H
29.8
35.0
|
L
 -4.1%
H
29.8
37.8
|
L
 14.8%
H
22.4
37.8
|
L
 -23.6%
H
22.4
48.1
|
L
 -73.6%
H
22.4
129.0
|
L
 -35.9%
H
22.4
274.0
|
| Genmab ADR |
|
17,790.5
|
28.7
|
L
 -0.6%
H
28.4
28.8
|
L
 0.2%
H
28.1
29.4
|
L
 -12.2%
H
28.1
33.7
|
L
 26.3%
H
21
33.7
|
L
 24.0%
H
17.2
33.7
|
L
 -27.6%
H
17.2
47.5
|
L
 -27.7%
H
17.2
49.1
|
L
 182.6%
H
9.2
49.1
|
| Genfit ADR |
|
194.5
|
3.9
|
L
 -1.8%
H
3.8
3.9
|
L
 0.8%
H
3.8
4.1
|
L
 -1.8%
H
3.6
4.5
|
L
 4.6%
H
3.4
4.6
|
L
 -31.9%
H
2.6
5.5
|
L
 2.9%
H
2.6
6.4
|
L
 -4.0%
H
2.6
7.2
|
L
H
2.6
26.3
|
| Genenta Science SpA ADR |
|
53.9
|
2.3
|
L
 0.4%
H
2.1
2.5
|
L
 -10.5%
H
2.1
2.8
|
L
 -27.2%
H
2.1
10
|
L
 -39.5%
H
2.1
10
|
L
 -52.7%
H
2.1
10
|
L
 -48.3%
H
2.1
10
|
L
H
2.1
13.1
|
L
H
2.1
13.1
|
| Grifols SA ADR Level III |
|
5,743.5
|
8.4
|
L
 1.0%
H
8.2
8.5
|
L
 -9.9%
H
8.2
9.9
|
L
 -12.0%
H
8.2
9.9
|
L
 -20.8%
H
8.2
10.8
|
L
 -11.2%
H
6.2
11.1
|
L
 20.7%
H
5.3
12.2
|
L
 -54.2%
H
5.3
20.5
|
L
 -51.8%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
8,024.8
|
68.2
|
L
 -0.2%
H
67.5
70
|
L
 4.7%
H
64.7
70.5
|
L
 3.4%
H
63.8
70.5
|
L
 9.9%
H
61.9
79.5
|
L
 14.4%
H
42.7
79.5
|
L
 47.5%
H
29.9
79.5
|
L
 81.1%
H
29.9
79.5
|
L
 267.1%
H
7.0
79.5
|
| HCW Biologics Inc |
|
6.5
|
3.0
|
L
 -9.0%
H
2.9
3.6
|
L
 -22.0%
H
2.9
3.8
|
L
 -25.1%
H
2.9
4.9
|
L
 -33.0%
H
2.8
7.4
|
L
 -82.1%
H
0.2
100.8
|
L
 -96.7%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
49.2
|
4.2
|
L
 1.0%
H
3.7
5.3
|
L
 42.0%
H
3.0
6.9
|
L
 38.7%
H
2.7
6.9
|
L
 232.5%
H
1.1
9.1
|
L
 215.0%
H
1.1
9.1
|
L
 -68.7%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
16.3
|
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -13.4%
H
1.2
1.4
|
L
 -19.6%
H
1.2
1.8
|
L
 -1.6%
H
1.1
2.1
|
L
 36.7%
H
0.7
3.8
|
L
 -72.1%
H
0.6
12.5
|
L
 -97.3%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
55.8
|
1.2
|
L
 -4.2%
H
1.1
1.2
|
L
 -12.2%
H
1.1
1.3
|
L
 -40.4%
H
1.1
2.1
|
L
 -2.5%
H
1.1
2.4
|
L
 -48.7%
H
0.6
2.4
|
L
 -51.7%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
| Harmony Biosciences Holdings |
|
1,810.3
|
31.4
|
L
 1.6%
H
30.6
32
|
L
 10.0%
H
27.7
32
|
L
 16.2%
H
25.5
32
|
L
 -8.1%
H
25.5
38.3
|
L
 -10.0%
H
25.5
40.9
|
L
 -45.0%
H
18.6
62.1
|
L
 -31.2%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,255.5
|
33.9
|
L
 -1.5%
H
32.7
34.1
|
L
 -10.2%
H
32.7
37.8
|
L
 -19.0%
H
32.7
42.4
|
L
 2.2%
H
29.8
50.7
|
L
 -32.0%
H
20.9
54.2
|
L
 192.0%
H
7.6
59.2
|
L
 588.2%
H
5.1
59.2
|
L
 444.6%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
201.7
|
1.1
|
L
H
1.1
1.1
|
L
 -5.2%
H
1.1
1.3
|
L
 -16.7%
H
1.1
1.4
|
L
 -40.2%
H
1.1
1.5
|
L
 -37.9%
H
1.0
2.7
|
L
 -67.8%
H
0.5
3.9
|
L
 -93.3%
H
0.5
22.4
|
L
 -95.8%
H
0.5
42.9
|
| Quantum BioPharma Ordinary |
|
34.0
|
8.9
|
L
 3.7%
H
8.0
9.0
|
L
 -19.5%
H
8.0
10.7
|
L
 -48.1%
H
8.0
17.5
|
L
 -65.7%
H
8.0
31.9
|
L
 77.8%
H
2.7
38.3
|
L
 -85.6%
H
2.7
136.5
|
L
 -91.0%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
249.1
|
1.3
|
L
 1.5%
H
1.2
1.3
|
L
 -20.4%
H
1.2
1.7
|
L
 -18.9%
H
1.2
1.9
|
L
 -46.2%
H
1.2
2.8
|
L
 -74.7%
H
1.2
6.8
|
L
 -61.1%
H
1.2
10.0
|
L
H
1.2
17.5
|
L
H
1.2
17.5
|
| HUTCHMED China ADR |
|
2,569.4
|
15.0
|
L
 -3.2%
H
14.9
15.1
|
L
 1.8%
H
14.7
15.8
|
L
 -6.5%
H
14.4
16.4
|
L
 -8.3%
H
14.4
18.3
|
L
 -20.1%
H
11.5
19.5
|
L
 45.7%
H
9.0
21.9
|
L
 -54.0%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
2,098.0
|
2.1
|
L
 0.5%
H
2
2.1
|
L
 -11.3%
H
2
2.4
|
L
 -14.8%
H
2
2.7
|
L
 -11.3%
H
2
3.0
|
L
 -59.8%
H
1.8
5.9
|
L
 -57.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Immucell Corp |
|
55.2
|
6.1
|
L
 -3.3%
H
6.1
6.3
|
L
 -2.2%
H
5.9
6.3
|
L
 -5.4%
H
5.9
7.0
|
L
 -0.7%
H
5.6
7.0
|
L
 72.8%
H
3.4
7.6
|
L
 -26.0%
H
3.3
8.5
|
L
 10.9%
H
3.3
13.2
|
L
 -9.6%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,651.0
|
30.2
|
L
 1.3%
H
28.8
30.5
|
L
 -5.1%
H
28.8
32.0
|
L
 12.3%
H
26.1
33.6
|
L
 34.9%
H
22.2
33.6
|
L
 -0.3%
H
13.5
33.6
|
L
 72.0%
H
13.3
47.7
|
L
 128.2%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx NV |
|
83.3
|
1.2
|
L
 2.5%
H
1.2
1.3
|
L
 -15.8%
H
1.2
1.5
|
L
 -10.9%
H
1.1
1.7
|
L
 50%
H
0.8
1.8
|
L
 -18.5%
H
0.7
2.8
|
L
 -54.3%
H
0.7
7.3
|
L
 -72.1%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
92.7
|
8.3
|
L
 -1.2%
H
8.1
8.4
|
L
 -4.8%
H
8.1
8.8
|
L
 -0.6%
H
7.2
9.1
|
L
 -43.6%
H
7.2
15.8
|
L
 -59.1%
H
7.2
23.3
|
L
 -70.0%
H
7.2
91.7
|
L
H
7.2
451.3
|
L
H
7.2
451.3
|
| Inhibikase Therapeutics Inc |
|
111.8
|
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 2.0%
H
1.3
1.8
|
L
 -7.4%
H
1.3
1.8
|
L
 -3.2%
H
1.3
1.9
|
L
 -42.8%
H
1.3
4.2
|
L
 -45.1%
H
0.8
6.9
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
| Illumina Inc |
|
18,626.3
|
121.9
|
L
 0.7%
H
119.4
122.1
|
L
 -1.3%
H
116.2
126
|
L
 26.1%
H
88
126
|
L
 27.6%
H
88
126
|
L
 -21.4%
H
68.7
154.4
|
L
 -43.9%
H
68.7
248.9
|
L
 -60.4%
H
68.7
555.8
|
L
 -21.8%
H
68.7
555.8
|
| IM Cannabis Corp |
|
6.8
|
1.3
|
L
 -2.3%
H
1.2
1.3
|
L
 -10.4%
H
1.2
1.5
|
L
 -36.1%
H
1.2
2.6
|
L
 -49.6%
H
1.2
3.1
|
L
 -33.9%
H
1.2
7.1
|
L
 -94.4%
H
0.4
25.2
|
L
 -99.6%
H
0.4
697.8
|
L
H
0.4
697.8
|
| Immix Biopharma Inc |
|
104.1
|
3.2
|
L
 4.0%
H
2.9
3.2
|
L
 -17.1%
H
2.9
3.9
|
L
 25.5%
H
2.3
4.1
|
L
 31.8%
H
1.9
4.1
|
L
 80%
H
1.3
4.1
|
L
 258.0%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immunome Inc |
|
1,340.5
|
15.2
|
L
 -1.7%
H
14.6
15.8
|
L
 -5.2%
H
14.6
17.9
|
L
 10.3%
H
13.5
17.9
|
L
 54.4%
H
8.7
17.9
|
L
 14.1%
H
5.2
17.9
|
L
 224.9%
H
2.2
31.0
|
L
 31.4%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
10.1
|
4
|
L
 1.0%
H
3.9
4.1
|
L
 -12.1%
H
3.8
4.6
|
L
 -25.0%
H
3.8
5.4
|
L
 -42.5%
H
3.8
7.3
|
L
 -67.6%
H
3.8
47.4
|
L
 -83.1%
H
3.8
54.8
|
L
 -96.3%
H
3.8
783
|
L
 -99.9%
H
3.8
7276.5
|
| Immuneering Corp Ordinary |
|
435.7
|
6.9
|
L
 4.1%
H
6.0
7.0
|
L
 0.3%
H
6.0
7.2
|
L
 12.8%
H
5.2
7.2
|
L
 96.3%
H
2.9
10.1
|
L
 257.0%
H
1.1
10.1
|
L
 -30.5%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics NV |
|
1,100.1
|
9.1
|
L
 -2.0%
H
8.7
9.1
|
L
 -11.2%
H
8.7
10.3
|
L
 -3.8%
H
8.7
11.3
|
L
 43.2%
H
5.1
11.3
|
L
 -2.7%
H
3.3
11.3
|
L
 -13.3%
H
3.3
13.8
|
L
 -8.8%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunic Inc |
|
71.0
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 -7.7%
H
0.7
0.8
|
L
 -18.2%
H
0.7
0.9
|
L
 -20%
H
0.7
1.1
|
L
 -40.5%
H
0.6
1.4
|
L
 -49.7%
H
0.6
3.2
|
L
 -95.8%
H
0.6
28.2
|
L
 -99.8%
H
0.6
472
|
| Immunovant Inc |
|
4,070.3
|
23.4
|
L
 -1.4%
H
22.6
23.7
|
L
 -5.4%
H
22.6
25.2
|
L
 44.9%
H
16.0
26.2
|
L
 48.4%
H
14.3
26.2
|
L
 -22.0%
H
12.7
31.7
|
L
 84.3%
H
11.5
45.6
|
L
 -52.8%
H
3.1
53.8
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
7.0
|
1.6
|
L
 -6.6%
H
1.5
1.8
|
L
 -20.5%
H
1.5
2.1
|
L
 -37.0%
H
1.5
2.7
|
L
 -27.9%
H
1.5
2.7
|
L
 384.4%
H
0.1
4.2
|
L
 -4.9%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,822.9
|
80.7
|
L
 -0.4%
H
76.0
82.2
|
L
 -1.2%
H
71
86.6
|
L
 140.9%
H
28.2
86.6
|
L
 278.1%
H
20.6
86.6
|
L
 392.6%
H
10.8
86.6
|
L
 177.5%
H
10.8
86.6
|
L
 324.0%
H
7.7
86.6
|
L
H
7.7
86.6
|
| Incyte |
|
20,806.3
|
106.0
|
L
 0.7%
H
103.8
106.4
|
L
 13.4%
H
91.2
106.5
|
L
 21.6%
H
82.8
106.5
|
L
 35.5%
H
77.7
106.5
|
L
 28.7%
H
53.6
106.5
|
L
 39.6%
H
50.3
106.5
|
L
 27.5%
H
50.3
106.5
|
L
 5.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
2.8
|
2.5
|
L
 -5.2%
H
2.5
2.7
|
L
 -21.1%
H
2.5
3.3
|
L
 -31.2%
H
2.5
5.3
|
L
 -62.3%
H
2.2
8.7
|
L
 113.5%
H
0.3
13.4
|
L
 40.3%
H
0.3
13.4
|
L
 -79.6%
H
0.3
36.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior Plc |
|
3,912.9
|
31.3
|
L
 -1.7%
H
30.4
32.0
|
L
 6.7%
H
29.6
32.4
|
L
 32.1%
H
23.0
32.4
|
L
 42.1%
H
21.8
32.4
|
L
 189.7%
H
7.6
32.4
|
L
 57.8%
H
3.1
32.4
|
L
 2017.6%
H
1.2
32.4
|
L
 944.7%
H
0.4
32.4
|
| MiNK Therapeutics Inc |
|
59.8
|
13.2
|
L
 -3.2%
H
13.1
13.8
|
L
 -5.8%
H
12.7
14.3
|
L
 -11.2%
H
12.7
15.4
|
L
 4.5%
H
11.6
18.2
|
L
 80%
H
0.9
76
|
L
 -47.6%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharmaceuticals Inc |
|
3.8
|
1.6
|
L
 -5.9%
H
1.6
1.7
|
L
 -14.9%
H
1.6
1.9
|
L
 -29.2%
H
1.6
2.5
|
L
 -28.6%
H
1.6
2.5
|
L
 -66.0%
H
1.6
8.3
|
L
 -96.9%
H
1.6
95
|
L
 -100.0%
H
1.6
4470
|
L
 -99.9%
H
1.6
32175
|
| INmune Bio Inc |
|
43.3
|
1.6
|
L
H
1.5
1.7
|
L
 -10.9%
H
1.5
1.9
|
L
 -16.8%
H
1.5
2.1
|
L
 -41.6%
H
1.5
2.6
|
L
 -73.8%
H
1.5
11.6
|
L
 -79.5%
H
1.5
14.7
|
L
 -78.8%
H
1.5
30.4
|
L
H
1.5
30.4
|
| Inovio Pharmaceuticals Inc |
|
112.7
|
2.1
|
L
 -5.8%
H
2.0
2.2
|
L
 -9.8%
H
2.0
2.6
|
L
 -11.3%
H
2.0
2.7
|
L
 47.2%
H
1.4
3.0
|
L
 -61.6%
H
1.3
5.6
|
L
 -1.4%
H
0.3
14.8
|
L
 -79.9%
H
0.3
19
|
L
 -68.5%
H
0.3
33.8
|
| Insmed Inc |
|
40,458.0
|
189.7
|
L
 2.2%
H
182.5
189.8
|
L
 0.1%
H
178.8
189.8
|
L
 16.9%
H
154.8
197.1
|
L
 73.6%
H
107.1
197.1
|
L
 164.6%
H
60.4
197.1
|
L
 944.0%
H
16.0
197.1
|
L
 482.4%
H
16.0
197.1
|
L
 1010.0%
H
9.0
197.1
|
| Innoviva Inc |
|
1,559.7
|
20.9
|
L
 1.4%
H
20.3
21.1
|
L
 14.6%
H
17.8
21.1
|
L
 21.3%
H
16.5
21.1
|
L
 13%
H
16.5
21.1
|
L
 4.3%
H
16.5
22
|
L
 60.1%
H
10.6
22
|
L
 104.9%
H
10.2
22
|
L
 129.0%
H
7.6
22
|
| IO Biotech Inc |
|
59.3
|
0.9
|
L
 7.1%
H
0.8
0.9
|
L
 -13.5%
H
0.8
1.0
|
L
 73.1%
H
0.5
1.2
|
L
 -52.4%
H
0.3
2.8
|
L
 -26.8%
H
0.3
2.8
|
L
 -64%
H
0.3
3.5
|
L
H
0.3
17.9
|
L
H
0.3
17.9
|
| Ionis Pharmaceuticals Inc |
|
11,913.2
|
73.6
|
L
 -0.7%
H
72.4
75
|
L
 -1.0%
H
71.5
76.8
|
L
 6.7%
H
69.4
76.8
|
L
 79.2%
H
40.4
76.8
|
L
 91.2%
H
24.0
76.8
|
L
 76.8%
H
24.0
76.8
|
L
 51.2%
H
24.0
76.8
|
L
 31.6%
H
19.6
86.6
|
| Iovance Biotherapeutics Inc |
|
837.3
|
2.3
|
L
 -0.4%
H
2.1
2.4
|
L
 16.8%
H
1.8
2.5
|
L
 5.5%
H
1.8
2.5
|
L
 -12.9%
H
1.8
2.8
|
L
 -81.3%
H
1.6
10.9
|
L
 -72.0%
H
1.6
18.3
|
L
 -94.3%
H
1.6
54.2
|
L
 -68.0%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
46.7
|
0.5
|
L
H
0.5
0.5
|
L
 -6.9%
H
0.5
0.7
|
L
 -3.6%
H
0.5
0.7
|
L
 1.9%
H
0.5
0.7
|
L
 -63.0%
H
0.3
1.8
|
L
 -94.8%
H
0.3
12.0
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,949.7
|
83.9
|
L
 -3.6%
H
83.1
87
|
L
 -2.8%
H
83.0
90.4
|
L
 23.5%
H
67.2
96.0
|
L
 46.9%
H
56.5
96.0
|
L
 32.4%
H
30.8
96.0
|
L
 384.7%
H
11.8
96.0
|
L
 -16.6%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Ironwood Pharmaceuticals Inc |
|
311.9
|
1.9
|
L
 -6.3%
H
1.9
2.1
|
L
H
1.8
2.2
|
L
 26.3%
H
1.4
2.2
|
L
 118.2%
H
0.8
2.2
|
L
 -58.8%
H
0.5
5.1
|
L
 -83.7%
H
0.5
15.7
|
L
 -82.0%
H
0.5
15.7
|
L
 -80.0%
H
0.5
17.7
|
| Iterum Therapeutics Plc |
|
28.8
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -10.5%
H
0.6
0.7
|
L
 -21.1%
H
0.6
0.8
|
L
 -14.3%
H
0.6
0.9
|
L
 -53.9%
H
0.6
3.0
|
L
 -62.5%
H
0.6
3.0
|
L
 -92.0%
H
0.6
44.9
|
L
H
0.6
195
|
| Invivyd Inc |
|
338.8
|
1.6
|
L
 2.6%
H
1.4
1.6
|
L
 -10.2%
H
1.4
1.9
|
L
 -3.1%
H
1.4
2.4
|
L
 110.7%
H
0.5
2.4
|
L
 58%
H
0.4
2.7
|
L
 -56.1%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| IMab ADR |
|
461.1
|
4
|
L
 -4.5%
H
3.8
4.1
|
L
 -19.2%
H
3.8
5.1
|
L
 -8.5%
H
3.8
6.8
|
L
 14.0%
H
3.2
6.8
|
L
 270.4%
H
0.6
6.8
|
L
 3.4%
H
0.6
7.7
|
L
 -88.8%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings plc ADR |
|
1,688.5
|
33.5
|
L
 6.0%
H
31.5
33.5
|
L
 1.2%
H
30.5
34.5
|
L
 -2.1%
H
30.5
35.0
|
L
 4.9%
H
30.5
38.2
|
L
 -2.4%
H
23.2
39.3
|
L
 -39.8%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep ADR |
|
248.8
|
1.7
|
L
 2.4%
H
1.7
1.7
|
L
 -10.6%
H
1.7
1.9
|
L
 -18.8%
H
1.7
2.3
|
L
 -6.6%
H
1.6
2.3
|
L
 -8.2%
H
1.3
2.7
|
L
 -19.9%
H
1.3
3.9
|
L
 -15.9%
H
1.3
8.0
|
L
 -54.0%
H
0.5
8.0
|
| Immuron ADR |
|
11.0
|
1.6
|
L
 -1.2%
H
1.5
1.7
|
L
 -13.7%
H
1.4
2
|
L
 -25.8%
H
1.4
2.4
|
L
 1.2%
H
1.4
2.4
|
L
 -12.8%
H
1.4
2.5
|
L
 -16.3%
H
1.4
6.0
|
L
 -73.7%
H
1.4
9.5
|
L
H
1.4
29.0
|
| Innate Pharma ADR |
|
164.1
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 -9.6%
H
1.7
2.0
|
L
 -8.7%
H
1.7
2.4
|
L
 -16.8%
H
1.7
2.4
|
L
 -3.3%
H
1.3
3.5
|
L
 -18.3%
H
1.3
4.0
|
L
 -57.1%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Inventiva ADR |
|
584.9
|
4.0
|
L
 -4.1%
H
3.9
4.2
|
L
 -6.7%
H
3.9
4.4
|
L
 -27.4%
H
3.8
8.0
|
L
 10.2%
H
3.4
8.0
|
L
 50.2%
H
2.1
8.0
|
L
 -6.7%
H
1.5
8.0
|
L
 -69.8%
H
1.5
19.1
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
6.6
|
1.8
|
L
 4.7%
H
1.6
2.1
|
L
 -8.3%
H
1.6
2.1
|
L
 -16.4%
H
1.6
2.4
|
L
 -15.2%
H
1.6
2.7
|
L
 79.8%
H
0.4
15.5
|
L
 -99.7%
H
0.4
720
|
L
 -99.9%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
| Janux Therapeutics Inc |
|
1,642.4
|
26.5
|
L
 -7.6%
H
24.9
29.1
|
L
 -7.8%
H
24.9
29.2
|
L
 16.7%
H
22.6
31.6
|
L
 17.3%
H
21.7
31.6
|
L
 -51.2%
H
21.7
71.7
|
L
 55.7%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharmaceuticals plc |
|
7,970.0
|
131.2
|
L
 -2.2%
H
128.8
133.2
|
L
 -4.7%
H
128.8
145.0
|
L
 -4.5%
H
128.8
145.0
|
L
 17.0%
H
109.9
145.0
|
L
 10.1%
H
95.5
148.1
|
L
 -9.8%
H
95.5
161.0
|
L
 -11.8%
H
95.5
189
|
L
 -8.0%
H
86.9
189
|
| Jasper Therapeutics Inc |
|
49.7
|
1.8
|
L
 -2.7%
H
1.6
1.8
|
L
 -21.9%
H
1.6
2.3
|
L
 -26.8%
H
1.6
2.7
|
L
 -34.8%
H
1.6
3.1
|
L
 -92.2%
H
1.6
26.1
|
L
 150.7%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharmaceuticals Inc |
|
5.0
|
0.7
|
L
 -2.7%
H
0.7
0.8
|
L
 -9.0%
H
0.7
0.8
|
L
 -56.7%
H
0.7
1.7
|
L
 -90.1%
H
0.7
20.6
|
L
 -89.7%
H
0.7
20.6
|
L
 -86.3%
H
0.7
56.7
|
L
 -99.8%
H
0.7
498.5
|
L
H
0.7
1337.5
|
| KalVista Pharmaceuticals Inc |
|
544.6
|
10.8
|
L
 -1.0%
H
10.4
10.9
|
L
 -1.2%
H
10.4
11.3
|
L
 -1.3%
H
10.4
12.2
|
L
 -14.9%
H
10.4
17.3
|
L
 -3.6%
H
7.3
17.3
|
L
 102.3%
H
5.0
17.3
|
L
 -36.7%
H
4.1
45
|
L
 -83.3%
H
4.1
67.2
|
| Kamada |
|
383.0
|
6.7
|
L
 0.6%
H
6.6
6.7
|
L
 -3.8%
H
6.6
7.0
|
L
 0.2%
H
6.6
7.2
|
L
 -5.5%
H
6.5
7.9
|
L
 11.4%
H
5.5
9.2
|
L
 52.8%
H
3.7
9.2
|
L
 -9.1%
H
3.7
9.2
|
L
 70.8%
H
3.3
13.3
|
| Kiniksa Pharmaceuticals |
|
2,908.3
|
38.4
|
L
 -0.7%
H
37.6
38.8
|
L
 3.7%
H
36.6
39.7
|
L
 0.7%
H
35.2
42.1
|
L
 15.9%
H
31.8
42.1
|
L
 66.8%
H
17.8
42.1
|
L
 151.8%
H
10.3
42.1
|
L
 151.6%
H
7.4
42.1
|
L
H
5.0
42.1
|
| Kodiak Sciences Inc |
|
931.2
|
17.6
|
L
 4.3%
H
15.8
17.7
|
L
 -2.7%
H
15.8
19.3
|
L
 23.9%
H
10.9
21.2
|
L
 115%
H
7.7
21.2
|
L
 266.5%
H
1.9
21.2
|
L
 150.8%
H
1.4
21.2
|
L
 -83.8%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Kiora Pharmaceuticals Inc |
|
8.0
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 0.9%
H
2.2
2.6
|
L
 -14.7%
H
2.2
3.0
|
L
 -2.5%
H
2.2
3.0
|
L
 -34.7%
H
2.2
4.2
|
L
 -61.4%
H
0.4
8.5
|
L
 -98.2%
H
0.4
327.2
|
L
 -99.9%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
88.0
|
5.2
|
L
 -1.2%
H
5.0
5.3
|
L
 -11.0%
H
5.0
6.2
|
L
 -10.6%
H
4.5
6.8
|
L
 30.0%
H
3.7
8.2
|
L
 -61%
H
0.6
14.2
|
L
 -93.3%
H
0.6
89.6
|
L
 -97.6%
H
0.6
270
|
L
 -97.8%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
493.6
|
16.2
|
L
 0.2%
H
15.9
16.8
|
L
 6.4%
H
14.9
16.8
|
L
 3.5%
H
13.6
16.8
|
L
 21.3%
H
13.2
16.8
|
L
 -75.9%
H
9.1
72.4
|
L
 -65.0%
H
9.1
73
|
L
 -70.8%
H
9.1
88.8
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
5,728.7
|
197.9
|
L
 -1.0%
H
192.5
200.1
|
L
 0.2%
H
184.0
213.0
|
L
 8.2%
H
179.2
213.0
|
L
 45.4%
H
133
213.0
|
L
 6.7%
H
122.8
213.0
|
L
 153.6%
H
69.8
219.3
|
L
 387.0%
H
38.9
219.3
|
L
H
8.0
219.3
|
| TuHURA Biosciences Inc |
|
129.2
|
2.5
|
L
 2.9%
H
2.4
2.5
|
L
 -1.2%
H
2.4
2.6
|
L
 0.8%
H
2.2
2.7
|
L
 3.7%
H
2.2
3.9
|
L
 -50.8%
H
1.8
7.2
|
L
 -98.6%
H
0.2
542.5
|
L
 -99.9%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
5.1
|
0.7
|
L
 -4.2%
H
0.7
0.7
|
L
 -14.8%
H
0.7
0.8
|
L
 -14.8%
H
0.7
0.8
|
L
 -1.4%
H
0.7
0.9
|
L
 -81.0%
H
0.7
3.9
|
L
 -35.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
858.0
|
9.9
|
L
 -3.0%
H
9.5
10.1
|
L
 -4.0%
H
8.8
10.5
|
L
 4.6%
H
8.8
11.1
|
L
 65.4%
H
5.5
11.1
|
L
 -44.5%
H
5.4
19.7
|
L
 -27.7%
H
5.4
24.2
|
L
 -72.4%
H
5.4
43
|
L
 -17.8%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
4,220.5
|
58.7
|
L
 -3.8%
H
56.8
60.3
|
L
 -5.1%
H
55.7
63.4
|
L
 3.1%
H
55.3
64.0
|
L
 43.6%
H
36.7
64.0
|
L
 18.3%
H
19.4
64.0
|
L
 102.0%
H
9.6
64.0
|
L
 33.5%
H
9.6
91.9
|
L
H
9.6
91.9
|
| Kezar Life Sciences Inc |
|
44.2
|
6.0
|
L
 -0.2%
H
6.0
6.1
|
L
 -2.7%
H
6.0
6.2
|
L
 56.5%
H
3.9
6.4
|
L
 51.8%
H
3.5
6.4
|
L
 -18.5%
H
3.5
7.7
|
L
 -91.4%
H
0.7
82.5
|
L
 -88.2%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics ADR |
|
12.2
|
7.3
|
L
 -2.3%
H
7.2
7.5
|
L
 -6.2%
H
7.2
8.0
|
L
 2.7%
H
6.5
8.0
|
L
 -11.0%
H
6.2
8.9
|
L
 -75.0%
H
2.9
34.4
|
L
 -79.1%
H
2.9
84
|
L
 -97.6%
H
2.9
792.5
|
L
 -98.6%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
23.1
|
1.0
|
L
 -3.7%
H
1
1.1
|
L
 2.0%
H
1.0
1.2
|
L
 23.8%
H
0.8
1.2
|
L
 25.3%
H
0.8
1.6
|
L
 -55.2%
H
0.8
2.9
|
L
 -52.3%
H
0.7
6.9
|
L
 -82.3%
H
0.7
12.5
|
L
 -79.9%
H
0.7
76.2
|
| Lifecore Biomedical Inc |
|
256.6
|
6.9
|
L
 3.5%
H
6.6
7.1
|
L
 -4.7%
H
6.6
7.2
|
L
 1.6%
H
6.3
7.4
|
L
 -11.7%
H
6.3
8.7
|
L
 7.2%
H
4.8
8.9
|
L
 -24.1%
H
1.5
11.5
|
L
 -27.4%
H
1.5
12.9
|
L
 -45.3%
H
1.5
15.6
|
| Lifevantage Corporation |
|
94.0
|
7.4
|
L
 9.6%
H
6.6
7.4
|
L
 -9.7%
H
6.6
8.2
|
L
 -20%
H
6.6
9.5
|
L
 -43.5%
H
6.6
15
|
L
 -46.3%
H
6.6
27.4
|
L
 91.2%
H
3.0
27.4
|
L
 -31.4%
H
3.0
27.4
|
L
 -12.7%
H
2.9
27.4
|
| Ligand Pharmaceuticals Inc |
|
4,177.0
|
202.5
|
L
 -2.8%
H
201.9
207.3
|
L
 5.8%
H
183.9
211.9
|
L
 10.6%
H
177.4
211.9
|
L
 38.4%
H
137.1
211.9
|
L
 55.9%
H
93.6
211.9
|
L
 222.2%
H
49.3
211.9
|
L
 263.2%
H
46.8
211.9
|
L
 232.9%
H
36.9
211.9
|
| Longeveron Inc Ordinary |
|
15.8
|
0.7
|
L
 -3.9%
H
0.7
0.8
|
L
 -10.8%
H
0.7
0.9
|
L
 -8.6%
H
0.7
1.0
|
L
 -41.7%
H
0.6
1.3
|
L
 -66.4%
H
0.6
2.3
|
L
 -97.8%
H
0.6
45.8
|
L
H
0.6
450
|
L
H
0.6
450
|
| Atyr Pharma Inc |
|
80.3
|
0.8
|
L
 6.5%
H
0.7
0.8
|
L
 -5.8%
H
0.7
0.9
|
L
 -2.4%
H
0.7
1.1
|
L
 -84.4%
H
0.7
6.5
|
L
 -73.6%
H
0.7
7.3
|
L
 -65.8%
H
0.7
7.3
|
L
 -74.1%
H
0.7
13.1
|
L
 -99.5%
H
0.7
175.6
|
| Lixte Biotechnology Holdings |
|
24.2
|
4.3
|
L
 -0.9%
H
4.1
4.4
|
L
 -0.9%
H
3.8
4.5
|
L
 -14.5%
H
3.8
5.1
|
L
 -12.9%
H
3.1
6.3
|
L
 165.6%
H
0.6
6.3
|
L
 -18.3%
H
0.6
27
|
L
 -93.8%
H
0.6
71.9
|
L
 -72.8%
H
0.6
110.4
|
| Lipocine Inc |
|
13.8
|
2.5
|
L
 -3.8%
H
2.5
2.6
|
L
 -4.5%
H
2.5
2.8
|
L
 -21.1%
H
2.5
3.3
|
L
 -14.8%
H
2.5
3.5
|
L
 -54.6%
H
2.5
5.9
|
L
 -62.9%
H
2.3
11.8
|
L
 -89.8%
H
2.3
41.1
|
L
 -98.6%
H
2.3
251.5
|
| Leap Therapeutics Inc |
|
26.1
|
0.5
|
L
 12.2%
H
0.4
0.5
|
L
 2.2%
H
0.4
0.5
|
L
 -27.0%
H
0.4
0.8
|
L
 43.8%
H
0.2
1.0
|
L
 -86.7%
H
0.2
3.6
|
L
 -94.0%
H
0.2
10.2
|
L
 -97.9%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
2,269.7
|
26.1
|
L
 1.9%
H
24.9
26.2
|
L
 7.1%
H
22.2
29.0
|
L
 8.6%
H
21.9
29.0
|
L
 35.8%
H
19.0
29.9
|
L
 140.9%
H
9.7
29.9
|
L
 428.1%
H
4.5
29.9
|
L
 479.8%
H
2.3
29.9
|
L
H
2.3
38.5
|
| Larimar Therapeutics Inc |
|
296.1
|
3.5
|
L
 -0.3%
H
3.2
3.5
|
L
 -11.1%
H
3.2
4.1
|
L
 -26.7%
H
3.2
5.0
|
L
 -5.5%
H
3.1
5.4
|
L
 -62.1%
H
1.6
9.5
|
L
 25.8%
H
1.6
13.7
|
L
 -80.6%
H
1.5
25.9
|
L
 -97.5%
H
1.5
219
|
| Lisata Therapeutics Inc |
|
18.0
|
2.1
|
L
 -12.3%
H
2.1
2.2
|
L
 -26.2%
H
2
2.8
|
L
 -16.6%
H
2
3.0
|
L
 -26.4%
H
2
3.0
|
L
 -29.2%
H
1.9
4.2
|
L
 -46.9%
H
1.9
4.5
|
L
 -91.0%
H
1.9
73.4
|
L
 -99.0%
H
1.9
210
|
| Lantern Pharma Inc |
|
36.9
|
3.4
|
L
 1.8%
H
3.0
3.5
|
L
 -14.7%
H
3.0
4
|
L
 -24.8%
H
3.0
4.7
|
L
 -31.5%
H
3.0
5.2
|
L
H
2.6
6.1
|
L
 -23.5%
H
2.4
12.0
|
L
 -79.1%
H
2.4
23.5
|
L
H
2.4
24.8
|
| LAVA Therapeutics NV |
|
42.4
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -0.6%
H
1.4
1.6
|
L
 5.2%
H
1.4
1.6
|
L
 -12.5%
H
0.9
2
|
L
 -67.1%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
| Lexicon Pharmaceuticals Inc |
|
454.2
|
1.3
|
L
 -12.6%
H
1.2
1.4
|
L
 -9.4%
H
1.2
1.5
|
L
 -17.8%
H
1.2
1.7
|
L
 11.6%
H
1.0
1.7
|
L
 -3.9%
H
0.3
1.7
|
L
 -41.3%
H
0.3
3.8
|
L
 16.8%
H
0.3
9.7
|
L
 -90.4%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
336.4
|
17.5
|
L
 -2.1%
H
16.6
17.7
|
L
 5.1%
H
15.7
18.0
|
L
 -1.0%
H
15.7
19.5
|
L
 54.7%
H
9.3
19.5
|
L
 -28.2%
H
7.7
25.4
|
L
 -84.0%
H
7.7
112.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Lyra Therapeutics Inc |
|
7.6
|
4.6
|
L
 -5.9%
H
4.5
4.9
|
L
 -20.0%
H
4.5
6.5
|
L
 -39.3%
H
4.5
8.1
|
L
 -33.1%
H
4.5
8.8
|
L
 -65.2%
H
3.8
37.5
|
L
 -98.0%
H
3.8
339.5
|
L
 -99.2%
H
3.8
825
|
L
H
3.8
1100
|
| Legend Biotech Corp ADR |
|
5,869.3
|
31.8
|
L
 -1.8%
H
31.0
32.1
|
L
 -1.9%
H
31.0
32.8
|
L
 1.2%
H
30.8
34.8
|
L
 -15.0%
H
30.8
38.4
|
L
 -22.3%
H
27.3
45.3
|
L
 -37.1%
H
27.3
77.3
|
L
 21.1%
H
23.4
77.3
|
L
H
23.4
77.3
|
| Mustang Bio Inc |
|
8.8
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -15.9%
H
1.2
1.5
|
L
 -30.3%
H
1.2
1.9
|
L
 -19.7%
H
1.2
1.9
|
L
 -90.2%
H
0.1
21.9
|
L
 -99.6%
H
0.1
554.2
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
137.7
|
2.1
|
L
 1.0%
H
1.9
2.1
|
L
 -8.1%
H
1.9
2.3
|
L
 -36.5%
H
1.9
3.3
|
L
 -29.8%
H
1.9
4.7
|
L
 118.1%
H
0.9
4.7
|
L
 -40.6%
H
0.8
4.7
|
L
 -71.8%
H
0.8
10.7
|
L
 -99.7%
H
0.8
1020.6
|
| Moleculin Biotech Inc |
|
24.3
|
0.5
|
L
 6.5%
H
0.4
0.5
|
L
 6.5%
H
0.4
0.6
|
L
 2.1%
H
0.4
0.6
|
L
 -27.9%
H
0.4
0.7
|
L
 -79.1%
H
0.3
3.7
|
L
 -96.4%
H
0.3
132.8
|
L
 -99.2%
H
0.3
132.8
|
L
H
0.3
862.2
|
| Seres Therapeutics Inc |
|
126.8
|
14.0
|
L
 1.2%
H
13.5
14.3
|
L
 -12.9%
H
12.5
16.7
|
L
 -30.2%
H
12.5
20.9
|
L
 -8.3%
H
12.5
24.7
|
L
 1847.2%
H
0.4
24.7
|
L
 78.4%
H
0.4
24.7
|
L
 -59.5%
H
0.4
38.5
|
L
 -55.6%
H
0.4
44.5
|
| Madrigal Pharmaceuticals Inc |
|
11,111.8
|
489.3
|
L
 0.1%
H
476.6
494.6
|
L
 16.8%
H
399
497.0
|
L
 12.1%
H
393.6
497.0
|
L
 42.9%
H
339.3
497.0
|
L
 37.9%
H
265
497.0
|
L
 656.7%
H
57.2
497.0
|
L
 294.9%
H
52.3
497.0
|
L
 2050.6%
H
5.3
497.0
|
| MediWound |
|
225.1
|
17.6
|
L
 -2.6%
H
17.5
18
|
L
 -4.2%
H
17.5
18.6
|
L
 0.1%
H
17.4
20.0
|
L
 -6.5%
H
16.1
20.3
|
L
 4.6%
H
14.1
22.5
|
L
 85.8%
H
7.1
24
|
L
 -32.7%
H
7.1
43.5
|
L
 -73.9%
H
7.1
73.3
|
| Lite Strategy Inc |
|
74.9
|
2.1
|
L
 14.1%
H
1.8
2.2
|
L
 0.5%
H
1.8
2.2
|
L
 -14.3%
H
1.8
3.0
|
L
 -58.8%
H
1.8
5.6
|
L
 -30.7%
H
1.5
9
|
L
 -65.5%
H
1.5
9
|
L
 -96.1%
H
1.5
91.5
|
L
 -94.1%
H
1.5
102.8
|
| Macrogenics Inc |
|
86.6
|
1.4
|
L
 0.7%
H
1.3
1.4
|
L
 -17.5%
H
1.3
1.7
|
L
 -20.4%
H
1.3
2.2
|
L
 -14.9%
H
1.3
2.2
|
L
 -69.3%
H
1.0
4.5
|
L
 -78.7%
H
1.0
21.9
|
L
 -93.1%
H
1.0
36.5
|
L
 -95.7%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
25.3
|
2.2
|
L
 20.1%
H
1.7
2.2
|
L
 6.3%
H
1.7
2.2
|
L
 -8.3%
H
1.7
2.8
|
L
 20.1%
H
1.4
2.8
|
L
 -6.8%
H
1.3
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
36.3
|
L
 -0.4%
H
35.3
36.6
|
L
 3.7%
H
32.3
37.5
|
L
 4.6%
H
32.2
38.7
|
L
 89.5%
H
18.1
40.2
|
L
 84.3%
H
16.6
40.2
|
L
 87.4%
H
5.1
40.2
|
L
 -64.0%
H
5.1
227.2
|
L
H
5.1
336
|
| MeiraGTx Holdings plc |
|
681.4
|
8.5
|
L
 0.7%
H
8.0
8.9
|
L
 -6.7%
H
8.0
9.2
|
L
 -0.2%
H
7.5
9.5
|
L
 11.2%
H
7.2
9.5
|
L
 25.9%
H
4.6
9.5
|
L
 23.1%
H
3.5
9.5
|
L
 -40.8%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharmaceuticals Inc |
|
3,500.4
|
68.1
|
L
 0.6%
H
66.8
69.3
|
L
 -6.3%
H
66.8
74
|
L
 -7.6%
H
66.8
78.5
|
L
 13.9%
H
57.8
78.5
|
L
 65.8%
H
36.9
78.5
|
L
 187.5%
H
17.5
78.5
|
L
 280.1%
H
12.8
78.5
|
L
H
6.5
78.5
|
| Milestone Pharmaceuticals Inc |
|
145.3
|
1.7
|
L
 -0.6%
H
1.7
1.8
|
L
 -10.9%
H
1.7
2.0
|
L
 -17.8%
H
1.7
2.1
|
L
 13.3%
H
1.5
2.3
|
L
 -13.2%
H
0.6
2.6
|
L
 -59.9%
H
0.6
5.2
|
L
 -73.3%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics |
|
753.1
|
10.6
|
L
 3.3%
H
9.8
10.6
|
L
 5.3%
H
9.8
10.8
|
L
 14.6%
H
8.8
11.0
|
L
 -79.5%
H
6.0
62.8
|
L
 -79.0%
H
6.0
62.8
|
L
 36.1%
H
6.0
65.0
|
L
 3.3%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,893.3
|
38.0
|
L
 2.7%
H
36.6
38.8
|
L
 -7.0%
H
36.6
42
|
L
 1.0%
H
36.6
44.8
|
L
 195.4%
H
12.6
44.8
|
L
 168.5%
H
8.2
44.8
|
L
H
5.9
44.8
|
L
H
5.9
44.8
|
L
H
5.9
44.8
|
| Mannkind Corp |
|
1,728.8
|
5.6
|
L
 -1.2%
H
5.5
5.7
|
L
 0.7%
H
5.4
6.2
|
L
 -0.4%
H
4.8
6.2
|
L
 64.1%
H
3.4
6.2
|
L
 -23.8%
H
3.4
7.5
|
L
 55.1%
H
3.2
7.6
|
L
 146.9%
H
2.3
7.6
|
L
 -60.8%
H
0.7
15.1
|
| Mind Medicine Inc |
|
1,137.5
|
11.7
|
L
 3.2%
H
10.6
11.7
|
L
 -17.6%
H
10.6
14.2
|
L
 -2.3%
H
10.6
14.4
|
L
 17.1%
H
8.7
14.4
|
L
 50.8%
H
4.7
14.4
|
L
 341.5%
H
2.1
14.4
|
L
 -14.7%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
69.6
|
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 -14.5%
H
1.3
1.7
|
L
 12.7%
H
1.2
2.0
|
L
 3.7%
H
1.2
2.0
|
L
 -9.6%
H
1.1
2.6
|
L
 -34.9%
H
1.1
2.7
|
L
 -76.1%
H
1.1
10.8
|
L
 -54.8%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
499.5
|
81.0
|
L
 0.2%
H
77.8
83.9
|
L
 -6.1%
H
77
86.2
|
L
 -17.8%
H
72
104
|
L
 101.9%
H
29.2
105
|
L
 414.6%
H
15.5
105
|
L
 309.9%
H
1.4
105
|
L
 268.8%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
11.1
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -13.1%
H
0.9
1.0
|
L
 -18.9%
H
0.9
1.1
|
L
 -30.1%
H
0.8
1.3
|
L
 -80.0%
H
0.8
6.0
|
L
 -79.0%
H
0.7
9.7
|
L
 -94.1%
H
0.7
37.7
|
L
 -99.0%
H
0.7
135.5
|
| Moderna |
|
9,570.6
|
24.5
|
L
 0.9%
H
23.0
24.6
|
L
 -9.7%
H
23.0
26.6
|
L
 -10.2%
H
23.0
29.5
|
L
 -7.8%
H
23.0
29.5
|
L
 -51.2%
H
23.0
50.9
|
L
 -85.0%
H
23.0
217.3
|
L
 -66.1%
H
23.0
497.5
|
L
H
11.5
497.5
|
| Mersana Therapeutics Inc |
|
42.0
|
8.4
|
L
 4.6%
H
7.5
8.4
|
L
 -12.2%
H
7.5
9.6
|
L
 5.7%
H
7.5
11.2
|
L
 27.2%
H
5.2
11.2
|
L
 -86.8%
H
5.2
70.8
|
L
 -94.9%
H
5.2
240.5
|
L
 -98.5%
H
5.2
727.3
|
L
H
5.2
727.3
|
| Merus NV |
|
7,222.7
|
95.2
|
L
 0.1%
H
95.1
95.4
|
L
 0.4%
H
94.8
95.4
|
L
 0.9%
H
94.3
95.4
|
L
 50.2%
H
62.2
95.4
|
L
 74.7%
H
33.2
95.4
|
L
 448.9%
H
12.4
95.4
|
L
 655.2%
H
12.0
95.4
|
L
H
7.3
95.4
|
| Maravai LifeSciences Holdings |
|
415.2
|
2.9
|
L
 -0.7%
H
2.5
2.9
|
L
 -8.6%
H
2.5
3.2
|
L
 -13.3%
H
2.5
3.7
|
L
 42.1%
H
2.0
3.7
|
L
 -63.9%
H
1.7
6.3
|
L
 -79.7%
H
1.7
16.9
|
L
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
17.5
|
9.2
|
L
 2.2%
H
9.0
9.4
|
L
 -9.7%
H
8.6
12.5
|
L
 3.5%
H
8.3
12.5
|
L
 21.4%
H
7.7
12.5
|
L
 18.1%
H
7.5
16.5
|
L
 -58.0%
H
6.8
24.1
|
L
 -43.9%
H
6.8
49.1
|
L
 -63.3%
H
6.5
49.1
|
| MaxCyte Inc |
|
153.5
|
1.4
|
L
 -2.0%
H
1.4
1.5
|
L
 -6.5%
H
1.4
1.7
|
L
 -7.1%
H
1.4
1.9
|
L
 0.7%
H
1.3
1.9
|
L
 -58.4%
H
1.3
5.2
|
L
 -78.8%
H
1.3
7.4
|
L
 -11.7%
H
1.3
17.4
|
L
H
1.3
17.4
|
| QC Technologies Inc |
|
8.9
|
3
|
L
 7.5%
H
2.7
3
|
L
 -24.1%
H
2.6
4.0
|
L
 -32.9%
H
2.6
5.9
|
L
 -69.4%
H
2.6
12.2
|
L
 -97.8%
H
2.6
164
|
L
 -100.0%
H
2.6
8940
|
L
 -99.9%
H
2.6
29850
|
L
 -100.0%
H
2.6
29850
|
| Mainz Biomed NV |
|
7.1
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -11.5%
H
1.3
1.5
|
L
 -20.6%
H
1.3
1.7
|
L
 -9.7%
H
1.3
1.9
|
L
 -85.1%
H
1.3
14.4
|
L
 -99.6%
H
1.3
384.5
|
L
H
1.3
1200
|
L
H
1.3
1200
|
| Mesoblast ADR |
|
1,874.4
|
14.6
|
L
 -2.1%
H
14.1
14.6
|
L
 -12.3%
H
14.1
16.4
|
L
 -19.2%
H
14.1
20.2
|
L
 -4.5%
H
12.7
20.2
|
L
 69.1%
H
8.8
22
|
L
 387%
H
1.0
22
|
L
 24.6%
H
1.0
22
|
L
 22.5%
H
1.0
22
|
| Molecular Partners AG ADR |
|
177.3
|
4.7
|
L
 1.3%
H
4.0
4.8
|
L
 30.6%
H
3.7
4.8
|
L
 27.8%
H
3.5
4.8
|
L
 29.5%
H
3.5
4.8
|
L
 -21.4%
H
3.4
6.2
|
L
 -24.3%
H
3.3
12.7
|
L
 -77.6%
H
3.3
32.0
|
L
 -87.6%
H
3.3
38.1
|
| Mereo Biopharma Group Plc |
|
286.2
|
1.8
|
L
 2.3%
H
1.7
1.8
|
L
 -5.3%
H
1.7
1.9
|
L
 -7.7%
H
1.7
2.3
|
L
 13.9%
H
1.5
2.3
|
L
 -56.0%
H
1.5
4.4
|
L
 119.5%
H
0.5
5.0
|
L
 -26.5%
H
0.3
5.0
|
L
H
0.3
8.5
|
| Natural Alternatives |
|
18.3
|
3.0
|
L
 1.7%
H
2.8
3.2
|
L
 8.8%
H
2.7
3.2
|
L
 9.2%
H
2.6
3.2
|
L
 -20%
H
2.6
4.0
|
L
 -34.8%
H
2.6
4.8
|
L
 -65.7%
H
2.6
10.1
|
L
 -62.5%
H
2.6
19.9
|
L
 -52.3%
H
2.6
19.9
|
| NewAmsterdam Pharma Company NV |
|
4,168.2
|
36.8
|
L
 -0.8%
H
35.5
37.8
|
L
 -3.1%
H
35.4
41.0
|
L
 14.1%
H
31.5
41.5
|
L
 60.1%
H
23.1
41.5
|
L
 62.4%
H
14.1
41.5
|
L
 264.7%
H
5.6
41.5
|
L
H
5.6
41.5
|
L
H
5.6
41.5
|
| Natures Sunshine Products |
|
313.5
|
17.9
|
L
 30.5%
H
16
17.9
|
L
 32.9%
H
13.2
17.9
|
L
 18.4%
H
13.0
17.9
|
L
 16.7%
H
13.0
17.9
|
L
 29.3%
H
11.0
18.1
|
L
 108.1%
H
7.9
21.7
|
L
 79.4%
H
7.9
21.7
|
L
 50.0%
H
5.5
21.7
|
| Nautilus Biotechnology Inc |
|
190.7
|
1.5
|
L
H
1.4
1.5
|
L
 13.5%
H
1.3
1.9
|
L
 73.6%
H
0.8
1.9
|
L
 104.1%
H
0.6
1.9
|
L
 -43.2%
H
0.6
2.7
|
L
 -28.4%
H
0.6
4.7
|
L
 -85.6%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
15,192.2
|
152.4
|
L
 -1.6%
H
149.0
154.5
|
L
 6.4%
H
139.5
157.7
|
L
 11.2%
H
133.6
157.7
|
L
 21.3%
H
123.7
157.7
|
L
 22.9%
H
84.2
157.7
|
L
 25.9%
H
84.2
158.0
|
L
 58.2%
H
71.9
158.0
|
L
 184.9%
H
31.3
158.0
|
| Minerva Neurosciences Inc |
|
25.9
|
3.7
|
L
 1.9%
H
3.5
3.9
|
L
 -11.7%
H
3.5
4.4
|
L
 70.2%
H
2.2
12.5
|
L
 106.1%
H
1.8
12.5
|
L
 59.9%
H
1.2
12.5
|
L
 37.9%
H
1.2
13.5
|
L
 -86.6%
H
1.2
32.9
|
L
 -90.9%
H
1.2
126.7
|
| Nektar Therapeutics |
|
1,064.5
|
56.0
|
L
 1.5%
H
55.0
58.0
|
L
 -13.8%
H
53.6
64.0
|
L
 -3.5%
H
52.9
66.9
|
L
 157.3%
H
22.0
66.9
|
L
 172.4%
H
6.5
66.9
|
L
 -1.8%
H
6.2
66.9
|
L
 -78.6%
H
6.2
401.3
|
L
 -71.0%
H
6.2
1670.4
|
| Nkarta Inc |
|
139.2
|
2.0
|
L
 -0.5%
H
1.8
2.0
|
L
 -7.1%
H
1.8
2.1
|
L
 -4.9%
H
1.8
2.7
|
L
 -2.5%
H
1.8
2.7
|
L
 -40.2%
H
1.3
3.8
|
L
 -83.1%
H
1.3
16.2
|
L
 -93.1%
H
1.3
79.2
|
L
H
1.3
79.2
|
| NewcelX |
|
18.3
|
4.0
|
L
 -3.4%
H
3.9
4.1
|
L
 -45.0%
H
3.9
6.5
|
L
 -78.1%
H
3.9
19.1
|
L
 -80.2%
H
3.9
28.0
|
L
 -89.9%
H
3.9
41.5
|
L
 -98.3%
H
1.2
752
|
L
H
1.2
2940
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
26.8
|
L
 0.3%
H
23.9
27.0
|
L
 -21.9%
H
23.9
33.1
|
L
 14.0%
H
23.1
37.3
|
L
 24.7%
H
16.8
37.3
|
L
 48.7%
H
14.7
37.3
|
L
 145.9%
H
7.5
37.3
|
L
 -88.0%
H
7.5
359
|
L
 -90.4%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7
|
L
 1.6%
H
6.8
7
|
L
 5.0%
H
6.6
7
|
L
 3.1%
H
6.4
7.1
|
L
 5.4%
H
6.4
7.5
|
L
 -1.7%
H
6.2
7.5
|
L
 212.5%
H
0.0
7.5
|
L
 -51.6%
H
0.0
45.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
22.0
|
0.9
|
L
 7.1%
H
0.8
1.1
|
L
 -8.1%
H
0.8
1.4
|
L
 -14.2%
H
0.8
1.4
|
L
 42.2%
H
0.6
1.7
|
L
 -66.0%
H
0.6
3.0
|
L
 -57.9%
H
0.4
6.8
|
L
 -99.4%
H
0.4
228.3
|
L
H
0.4
16192.5
|
| Nurix Therapeutics Inc |
|
1,247.9
|
12.3
|
L
 -1.7%
H
11.7
12.4
|
L
 -4.9%
H
11.7
13.2
|
L
 25.2%
H
9
13.2
|
L
 22.2%
H
8.2
13.2
|
L
 -55.8%
H
8.2
29.6
|
L
 -5.5%
H
4.2
29.6
|
L
 -46.9%
H
4.2
52.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics |
|
27.5
|
0.9
|
L
 -9.7%
H
0.9
1.0
|
L
 -17.0%
H
0.9
1.1
|
L
 -19.1%
H
0.9
1.3
|
L
 -28.5%
H
0.9
2.0
|
L
 -27.9%
H
0.8
2.6
|
L
 -37.6%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharmaceuticals Inc |
|
58.2
|
2.5
|
L
 -8.2%
H
2.4
2.7
|
L
 -21.0%
H
2.4
3.1
|
L
 -33.2%
H
2.4
3.8
|
L
 -0.4%
H
2.3
3.8
|
L
 88.5%
H
1.1
6.0
|
L
 -72.3%
H
1.1
54
|
L
 -97.7%
H
1.1
769.9
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,049.0
|
9.5
|
L
 -22.7%
H
9.0
10.1
|
L
 -24.6%
H
9.0
13.7
|
L
 -53.4%
H
9.0
28.3
|
L
 -16.9%
H
9.0
28.3
|
L
 -40.5%
H
5.9
28.3
|
L
 -80.4%
H
5.9
57.5
|
L
 -66.1%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc Ordinary Shares |
|
6,787.2
|
93.4
|
L
 -2.6%
H
91.7
95.9
|
L
 -6.0%
H
89.0
99.8
|
L
 12.0%
H
82.5
104.9
|
L
 29.4%
H
71.1
104.9
|
L
 -0.8%
H
55.5
104.9
|
L
 200.5%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,207.9
|
7.4
|
L
 -2.0%
H
7.3
7.6
|
L
 -11.4%
H
7.3
8.4
|
L
 -19.3%
H
7.3
9.6
|
L
 -15.3%
H
7.2
10.6
|
L
 -19.0%
H
5.0
11.6
|
L
 -61.7%
H
3.5
25.7
|
L
 -91.7%
H
3.5
331.7
|
L
 -95.4%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
157.3
|
6.1
|
L
 8.3%
H
5.6
6.2
|
L
 -8.5%
H
5.6
6.7
|
L
 0.5%
H
5.6
7
|
L
 -0.5%
H
5.6
7
|
L
 -28.3%
H
4.4
11.8
|
L
 -12.9%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
24.0
|
9.0
|
L
 -8.8%
H
9.0
10.6
|
L
 -28.9%
H
9.0
12.5
|
L
 46.2%
H
6.2
13.2
|
L
 75.7%
H
4.8
13.2
|
L
 -43.4%
H
2.8
19.2
|
L
 -56.3%
H
2.8
30.8
|
L
 -92.4%
H
2.8
172.8
|
L
H
2.8
1308
|
| NuCana plc ADR |
|
7.0
|
3.7
|
L
 1.1%
H
3.6
3.9
|
L
 -8.2%
H
3.6
4.0
|
L
 -47.6%
H
3.6
6.7
|
L
 -44.2%
H
2.8
8
|
L
 -100.0%
H
2.8
66400
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
| Ocugen Inc |
|
424.8
|
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -12.8%
H
1.3
1.6
|
L
 -22.7%
H
1.3
1.9
|
L
 36%
H
1.0
1.9
|
L
 25.9%
H
0.5
1.9
|
L
 -11.1%
H
0.3
2.1
|
L
 385.7%
H
0.3
18.8
|
L
 -99.5%
H
0.2
282.6
|
| Oculis Holding AG |
|
1,111.6
|
19.2
|
L
 -0.9%
H
19.0
19.6
|
L
 -0.3%
H
19
20.1
|
L
 0.9%
H
19
22
|
L
 5.7%
H
16
22
|
L
 14.5%
H
14
23.1
|
L
 92.5%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
| Ocular Therapeutix Inc |
|
2,311.6
|
10.9
|
L
 2.1%
H
10.3
10.9
|
L
 -7.0%
H
10.3
11.7
|
L
 -5.8%
H
10.3
12.5
|
L
 -11.8%
H
10.3
13.9
|
L
 0.7%
H
5.8
13.9
|
L
 205.6%
H
2
13.9
|
L
 -15.5%
H
2
24.3
|
L
 -1.0%
H
2
24.3
|
| Opus Genetics Inc |
|
119.8
|
2
|
L
 -1.5%
H
1.9
2.1
|
L
 -13.0%
H
1.9
2.4
|
L
 -1.5%
H
1.9
2.4
|
L
 83.5%
H
1.0
2.4
|
L
 72.4%
H
0.7
2.4
|
L
 -3.8%
H
0.7
6.6
|
L
 -66.7%
H
0.7
13.8
|
L
 -99.1%
H
0.7
340.8
|
| Insight Molecular Diagnostics |
|
178.6
|
6.2
|
L
 -4%
H
6.1
6.5
|
L
 3.8%
H
5.8
6.8
|
L
 69.6%
H
3.6
6.8
|
L
 138.2%
H
2.3
6.8
|
L
 119.7%
H
1.9
6.8
|
L
 -52.5%
H
1.9
13.8
|
L
 -80.3%
H
1.9
131.4
|
L
H
1.9
204.8
|
| OKYO Pharma Ordinary Shares |
|
92.1
|
2.5
|
L
 -6.8%
H
2.3
2.6
|
L
 -10.6%
H
2.3
2.8
|
L
 20.7%
H
1.9
2.8
|
L
 -22.5%
H
1.9
3.4
|
L
 116.8%
H
0.9
3.4
|
L
 2.1%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharmaceuticals Inc |
|
573.1
|
8.4
|
L
 2.0%
H
7.9
8.4
|
L
 -6.9%
H
7.8
9.2
|
L
 -20.0%
H
6.7
11.3
|
L
 76.9%
H
4.5
11.5
|
L
 -33.1%
H
2.9
13.1
|
L
 160.9%
H
2.2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
| Omeros Corporation |
|
448.5
|
6.6
|
L
 0.2%
H
6.3
6.6
|
L
 -10.1%
H
6.3
7.4
|
L
 48.4%
H
4.1
12.1
|
L
 74.3%
H
3.8
12.1
|
L
 46.4%
H
3.0
13.6
|
L
 100.9%
H
0.9
13.6
|
L
 -36.9%
H
0.9
23.9
|
L
 -52.1%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
106.6
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -14.3%
H
0.9
1.2
|
L
 -24.4%
H
0.9
1.4
|
L
 10.9%
H
0.8
1.5
|
L
 -4.7%
H
0.3
1.5
|
L
 -32%
H
0.3
3.4
|
L
 -53.2%
H
0.3
4.8
|
L
 -68.2%
H
0.3
8.5
|
| Traws Pharma Inc |
|
13.9
|
2.0
|
L
 -3.5%
H
1.9
2.1
|
L
 -24.1%
H
1.9
2.7
|
L
 -22%
H
1.9
3.3
|
L
 31.8%
H
1.3
3.3
|
L
 -61.5%
H
1.0
19.4
|
L
 -88.4%
H
1.0
37.3
|
L
 -98.0%
H
1.0
723.8
|
L
 -100.0%
H
1.0
106312.5
|
| VivoSim Labs Inc |
|
5.7
|
2.2
|
L
 -0.5%
H
2.1
2.2
|
L
 -19.3%
H
2.0
2.7
|
L
 -30.1%
H
2.0
3.5
|
L
 24.6%
H
1.7
5.3
|
L
 -57.8%
H
0.3
22.0
|
L
 -88.3%
H
0.3
40.8
|
L
 -98.1%
H
0.3
287.0
|
L
 -99.7%
H
0.3
1197.6
|
| ORIC Pharmaceuticals Inc |
|
1,199.5
|
12.4
|
L
 -1.6%
H
11.8
12.6
|
L
 -6.2%
H
11.8
13.4
|
L
 -12.5%
H
11.7
14.6
|
L
 28.3%
H
9.0
14.9
|
L
 24.1%
H
3.9
14.9
|
L
 406.1%
H
2.4
16.7
|
L
 -48.6%
H
2.4
40.8
|
L
H
2.4
40.8
|
| Oramed Pharmaceuticals Inc |
|
87.3
|
2.2
|
L
 -0.5%
H
2.1
2.2
|
L
 -8.4%
H
2.1
2.4
|
L
 -11.7%
H
2.1
2.5
|
L
 5.3%
H
2.0
2.7
|
L
 -8.0%
H
1.8
3.1
|
L
 -67.4%
H
1.7
13.7
|
L
 -19.2%
H
1.7
31.5
|
L
 -66.7%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
52.9
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -5.6%
H
1.1
1.3
|
L
 1.7%
H
1.1
1.5
|
L
 -35.3%
H
0.8
3.0
|
L
 -82.2%
H
0.8
6.8
|
L
 -99.7%
H
0.8
812
|
L
 -99.6%
H
0.8
1704
|
L
H
0.8
17568
|
| Ovid Therapeutics Inc |
|
93.9
|
1.3
|
L
 -0.8%
H
1.2
1.3
|
L
 -5.0%
H
1.2
1.4
|
L
 -21.0%
H
1.2
1.9
|
L
 158.8%
H
0.5
2.0
|
L
 1.5%
H
0.2
2.0
|
L
 -8.3%
H
0.2
4.1
|
L
 -73.5%
H
0.2
7.0
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp |
|
1,773.8
|
43.8
|
L
 1.7%
H
41.8
43.9
|
L
 4.0%
H
40.0
44.4
|
L
 16.3%
H
35.8
44.4
|
L
 60.1%
H
27.3
44.4
|
L
 86.2%
H
16.2
44.4
|
L
 193.5%
H
9.4
44.4
|
L
 149.6%
H
9.4
44.4
|
L
 33.5%
H
9.4
54.6
|
| Palisade Bio Inc |
|
250.6
|
1.7
|
L
 1.2%
H
1.5
1.7
|
L
 -18.8%
H
1.5
2.0
|
L
H
1.5
2.3
|
L
 90.9%
H
0.5
2.3
|
L
 -33.9%
H
0.5
3.3
|
L
 -97.4%
H
0.4
128.1
|
L
 -99.9%
H
0.4
12015
|
L
 -100.0%
H
0.4
1474200
|
| Passage Bio Inc |
|
20.0
|
6.3
|
L
 -3.5%
H
6.2
6.5
|
L
 -18.2%
H
6.2
7.9
|
L
 -21.0%
H
6.2
9
|
L
 11.9%
H
5.5
9
|
L
 -51.8%
H
5.1
26.6
|
L
 -73.8%
H
5.1
38.4
|
L
 -98.1%
H
5.1
617.4
|
L
H
5.1
764.6
|
| Paranovus Entertainment |
|
38.4
|
0.6
|
L
 -5%
H
0.6
0.6
|
L
 -5%
H
0.6
0.7
|
L
 -43.6%
H
0.5
1.2
|
L
 -20.8%
H
0.5
1.2
|
L
 -38.7%
H
0.5
1.5
|
L
 -78.0%
H
0.3
6.7
|
L
 -98.4%
H
0.3
51.6
|
L
H
0.3
122
|
| Puma Biotechnology Inc |
|
301.7
|
6.0
|
L
 22.2%
H
5.0
6.0
|
L
 17.5%
H
4.8
6.0
|
L
 15.6%
H
4.8
6.0
|
L
 82.1%
H
3.1
6.1
|
L
 97.7%
H
2.3
6.1
|
L
 91.4%
H
2.1
7.7
|
L
 -23.0%
H
1.6
14.1
|
L
 -93.3%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
980.3
|
22.1
|
L
 4.5%
H
20.3
23.9
|
L
 3.1%
H
20.3
23.9
|
L
 -6.7%
H
19.8
23.9
|
L
 -7.2%
H
19.8
27.6
|
L
 24.6%
H
16
27.6
|
L
 -56.2%
H
11.2
53.3
|
L
 -56.3%
H
11.2
82.2
|
L
 -61.2%
H
11.2
82.2
|
| Processa Pharmaceuticals Inc |
|
17.3
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -20.5%
H
0.3
0.4
|
L
 -13.9%
H
0.3
0.6
|
L
 34.8%
H
0.2
0.6
|
L
 -73.0%
H
0.2
1.5
|
L
 -85.3%
H
0.2
5.9
|
L
 -92.7%
H
0.2
14.2
|
L
 -98.8%
H
0.2
35.9
|
| Vaxcyte Inc |
|
5,452.2
|
41.7
|
L
 -0.1%
H
40.1
42.1
|
L
 -8.0%
H
39.9
46.0
|
L
 -0.5%
H
39.9
46.0
|
L
 38.8%
H
29.3
46.0
|
L
 -59.4%
H
27.7
107.2
|
L
 -3.9%
H
27.7
121.1
|
L
 15.8%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS Biotechnology Corporation |
|
42.4
|
0.9
|
L
 2.3%
H
0.9
0.9
|
L
 -3.2%
H
0.9
1.0
|
L
 -5.2%
H
0.9
1.2
|
L
 -18.8%
H
0.9
1.5
|
L
 -72.5%
H
0.9
3.4
|
L
 -82.9%
H
0.9
13.7
|
L
 -61.8%
H
0.9
17.9
|
L
 -99.7%
H
0.6
356.4
|
| PepGen Inc |
|
317.6
|
4.6
|
L
 9.7%
H
4.1
4.6
|
L
 -0.9%
H
4.1
4.9
|
L
 -5.9%
H
4.1
5.7
|
L
 288.2%
H
1.0
6.3
|
L
 -17.9%
H
0.9
6.9
|
L
 -60.6%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,376.4
|
3.9
|
L
 -0.5%
H
3.6
3.9
|
L
 -5.8%
H
3.6
4.4
|
L
 17.8%
H
3.0
4.5
|
L
 107.5%
H
1.7
5.2
|
L
 310.5%
H
0.7
5.2
|
L
 145.3%
H
0.7
5.2
|
L
 -20.6%
H
0.7
11.1
|
L
 -90%
H
0.7
43.8
|
| Phathom Pharmaceuticals Inc |
|
942.6
|
13.3
|
L
 1.6%
H
12.3
13.3
|
L
 -2.2%
H
12.3
14.2
|
L
 22.2%
H
10.6
16.1
|
L
 41.0%
H
9.3
16.1
|
L
 -28.4%
H
2.2
19.0
|
L
 30.2%
H
2.2
19.7
|
L
 -68.2%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Phio Pharmaceuticals Corp |
|
8.9
|
1.6
|
L
 5.4%
H
1.4
1.6
|
L
 -23.9%
H
1.4
4.2
|
L
 -33.6%
H
1.4
4.2
|
L
 -30.7%
H
1.4
4.2
|
L
 -52%
H
1.0
9.8
|
L
 -97.4%
H
0.6
110.4
|
L
 -99.4%
H
0.6
470.9
|
L
 -100.0%
H
0.6
267597
|
| Pharvaris NV |
|
1,388.2
|
21.6
|
L
 -1.0%
H
21.0
22.3
|
L
 -2.8%
H
21.0
23.8
|
L
 -3.8%
H
20.7
24.2
|
L
 6.3%
H
19.6
25.9
|
L
 -3.3%
H
11.5
26.3
|
L
 529.4%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
98.2
|
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 -4.8%
H
1.5
1.7
|
L
 8.1%
H
1.5
2.0
|
L
 -4.8%
H
1.4
2.0
|
L
 -89.6%
H
1.1
15.9
|
L
 -92.6%
H
1.1
36.6
|
L
 -92.7%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
26.8
|
3.3
|
L
 1.2%
H
3.3
3.3
|
L
 -15.6%
H
3.2
4.0
|
L
 -23.5%
H
3.2
4.6
|
L
 -31.9%
H
3.2
5.7
|
L
 -27.4%
H
3.2
7.1
|
L
 -43.7%
H
0.7
11.6
|
L
 -95.8%
H
0.7
94.8
|
L
 -97.6%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
5.8
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -8.6%
H
0.8
0.9
|
L
 -15.8%
H
0.8
1.1
|
L
H
0.8
1.3
|
L
 -53.0%
H
0.8
1.9
|
L
 -70.8%
H
0.8
3.2
|
L
 -92.1%
H
0.8
55.5
|
L
 -99.4%
H
0.8
253.4
|
| Praxis Precision Medicines Inc |
|
4,206.7
|
168.2
|
L
 -2.4%
H
159.7
172
|
L
 -15.4%
H
154.5
186.7
|
L
 223.3%
H
50.6
206.7
|
L
 255.9%
H
37.2
206.7
|
L
 131.6%
H
26.7
206.7
|
L
 431.5%
H
11.9
206.7
|
L
 -67.4%
H
11.9
914.3
|
L
H
11.9
914.3
|
| PainReform |
|
2.0
|
1
|
L
 -7.4%
H
1
1.0
|
L
 -19.4%
H
0.9
1.3
|
L
 -26.5%
H
0.9
1.5
|
L
 -24.2%
H
0.9
3.6
|
L
 66.7%
H
0.5
16.6
|
L
 -96.7%
H
0.2
158.5
|
L
 -99.6%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
67.4
|
1.2
|
L
 -11.9%
H
1.2
1.3
|
L
 -25.2%
H
1.2
4.2
|
L
 -17.4%
H
1.2
4.2
|
L
 38.4%
H
0.8
4.2
|
L
 -9.9%
H
0.6
4.2
|
L
 -84.5%
H
0.6
8.7
|
L
 -97.3%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
679.2
|
3.8
|
L
 -8.9%
H
3.6
4.1
|
L
 -22.9%
H
3.6
5.0
|
L
 -35.1%
H
3.6
6.9
|
L
 3.5%
H
3.1
6.9
|
L
 -7.1%
H
1.1
6.9
|
L
 -79.0%
H
1.1
21.7
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
393.0
|
2.9
|
L
 2.9%
H
2.6
3.0
|
L
 -5.6%
H
2.6
3.1
|
L
 -2.4%
H
2.6
3.5
|
L
 12.9%
H
2.1
3.5
|
L
 49.7%
H
0.5
7.1
|
L
 -72.5%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProPhase Labs Inc |
|
11.6
|
0.3
|
L
H
0.3
0.3
|
L
 -22.2%
H
0.3
0.4
|
L
 -54.1%
H
0.3
0.6
|
L
 -15.2%
H
0.3
0.7
|
L
 -80.4%
H
0.2
0.9
|
L
 -97.7%
H
0.2
12.7
|
L
 -97.0%
H
0.2
16.0
|
L
 -79.4%
H
0.2
16.0
|
| ProQR Therapeutics NV |
|
233.9
|
2.2
|
L
 0.5%
H
2.0
2.2
|
L
 -19.3%
H
2.0
2.8
|
L
 -2.2%
H
2.0
3.1
|
L
 8.3%
H
1.8
3.1
|
L
 -37.8%
H
1.1
4.2
|
L
 141.3%
H
0.9
4.6
|
L
 -47.1%
H
0.5
9.5
|
L
 -82.8%
H
0.5
24
|
| Prothena Corporation plc |
|
568.4
|
10.6
|
L
 4.8%
H
9.7
11.0
|
L
 -1.8%
H
9.7
11.2
|
L
 3.8%
H
9.6
11.7
|
L
 36.8%
H
7.4
11.7
|
L
 -39.6%
H
4.3
18.6
|
L
 -81.1%
H
4.3
79.7
|
L
 -14.2%
H
4.3
79.8
|
L
 -82.9%
H
4.3
79.8
|
| AlphaTON Capital Corp |
|
25.0
|
3.9
|
L
 -14.2%
H
3.6
4.2
|
L
 -23.4%
H
3.6
5.1
|
L
 -29.4%
H
3.6
13.8
|
L
 -60.5%
H
3.6
13.8
|
L
 -20.7%
H
3.0
15.8
|
L
 -96.9%
H
2.1
153.4
|
L
 -97.9%
H
2.1
899.5
|
L
 -98.7%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
74.2
|
0.5
|
L
 5.9%
H
0.5
0.5
|
L
H
0.5
0.6
|
L
 -34.2%
H
0.5
0.8
|
L
 -29.0%
H
0.4
0.9
|
L
 -60.3%
H
0.2
2.3
|
L
 -91.4%
H
0.2
7.5
|
L
 -98.4%
H
0.2
81.3
|
L
 -100.0%
H
0.2
46125
|
| PTC Therapeutics Inc |
|
5,763.1
|
71.8
|
L
 -1.1%
H
69.2
72.9
|
L
 5.1%
H
66.1
74.0
|
L
 12.3%
H
63.3
74.0
|
L
 42.5%
H
43.2
74.0
|
L
 67.1%
H
36.0
74.0
|
L
 107.0%
H
17.5
74.0
|
L
 20.9%
H
17.5
74.0
|
L
 155.5%
H
4.0
74.0
|
| Protagonist Therapeutics Inc |
|
5,072.5
|
79.5
|
L
 -0.3%
H
76.7
80.8
|
L
 1.2%
H
75.4
80.8
|
L
 21.5%
H
64.5
93.3
|
L
 56.1%
H
50.5
93.3
|
L
 67.1%
H
33.3
93.3
|
L
 926.3%
H
7.2
93.3
|
L
 273.8%
H
6.9
93.3
|
L
H
4.5
93.3
|
| Protagenic Therapeutics Inc |
|
4.0
|
2.1
|
L
 0.5%
H
2.0
2.1
|
L
 -19.8%
H
1.9
2.5
|
L
 -38.7%
H
1.9
3.8
|
L
 -27.0%
H
1.9
6.2
|
L
 227.0%
H
0.2
14.3
|
L
 -12.7%
H
0.2
14.3
|
L
 -51.0%
H
0.2
28
|
L
 -100.0%
H
0.2
2200044.7
|
| Pulmatrix Inc |
|
17.7
|
4.9
|
L
 1.5%
H
4.6
4.9
|
L
 -1.6%
H
4.6
5.0
|
L
 4.3%
H
4.4
5.2
|
L
 -5.8%
H
4.3
5.5
|
L
 133.2%
H
2
10.4
|
L
 37.0%
H
1.6
10.4
|
L
 -78.9%
H
1.6
60.8
|
L
 -99.4%
H
1.6
1396
|
| Polypid |
|
58.0
|
3.7
|
L
 -4.0%
H
3.6
3.8
|
L
 -4.7%
H
3.6
3.9
|
L
 9.6%
H
3.1
3.9
|
L
 13.7%
H
3.1
3.9
|
L
 7.4%
H
2.3
3.9
|
L
 -85.0%
H
2.3
38.7
|
L
 -98.8%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
243.5
|
3.9
|
L
 -3.2%
H
3.7
4.0
|
L
 9.8%
H
3.5
4.2
|
L
 53.3%
H
2.6
4.2
|
L
 265.4%
H
1.0
4.2
|
L
 -0.8%
H
0.8
5.4
|
L
 155.6%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Group NV ADR |
|
1,057.2
|
15.4
|
L
 5.0%
H
14.6
16.3
|
L
 17.8%
H
12.7
16.5
|
L
 5.2%
H
12.7
16.5
|
L
 27%
H
11
17.1
|
L
 85.7%
H
7.3
17.1
|
L
 35.4%
H
6.7
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
| Purple Biotech ADR |
|
7.4
|
0.8
|
L
 10.8%
H
0.7
0.8
|
L
 5.1%
H
0.7
0.9
|
L
 41.4%
H
0.6
1.4
|
L
 -61.9%
H
0.5
2.4
|
L
 -70.7%
H
0.5
13.4
|
L
 -98.1%
H
0.5
47.4
|
L
 -99.0%
H
0.5
145
|
L
H
0.5
1390
|
| PureTech Health Plc ADR |
|
422.9
|
17.5
|
L
 1.5%
H
17.0
17.5
|
L
 -1.6%
H
16.6
17.9
|
L
 -4.7%
H
16.6
18.9
|
L
 -2.5%
H
14.5
19.8
|
L
 -15.9%
H
13.3
25.0
|
L
 -36.5%
H
13.3
38.9
|
L
H
13.3
65.9
|
L
H
13.3
65.9
|
| Qualigen Therapeutics Inc |
|
5.1
|
2.5
|
L
 -2.7%
H
2.4
2.5
|
L
 -12.3%
H
2.4
2.9
|
L
 -50.3%
H
2.4
6.0
|
L
 35.1%
H
1.6
8.8
|
L
 -44.8%
H
1.6
8.8
|
L
 -97.6%
H
0.1
118.8
|
L
 -99.9%
H
0.1
2330
|
L
 -100.0%
H
0.1
468750
|
| Qilian International Holding |
|
1,946.0
|
9.7
|
L
 5.4%
H
9.3
9.7
|
L
 2.5%
H
8.9
10.1
|
L
 0.1%
H
8.8
10.4
|
L
 26.5%
H
7
11.8
|
L
 27.6%
H
6.2
17.2
|
L
 67.2%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
| Quince Therapeutics Inc |
|
83.8
|
1.6
|
L
 -1.9%
H
1.5
1.6
|
L
 -5.5%
H
1.5
1.7
|
L
 -12.4%
H
1.5
2.2
|
L
 -6.6%
H
1.5
2.2
|
L
 1.3%
H
0.7
2.5
|
L
 83.5%
H
0.5
2.5
|
L
 -96.8%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
1,712.0
|
27.8
|
L
 1.0%
H
25.6
28.4
|
L
 -59.0%
H
22.9
36.2
|
L
 -52.0%
H
22.9
71.5
|
L
 106.6%
H
12.9
71.5
|
L
 274.0%
H
5.5
71.5
|
L
 47.3%
H
3.7
71.5
|
L
 -32.2%
H
3.7
71.5
|
L
 50.1%
H
3.7
82.5
|
| Quoin Pharmaceuticals ADR |
|
5.4
|
9.0
|
L
 5.1%
H
8.1
9.3
|
L
 -20.3%
H
8.1
11.8
|
L
 15.5%
H
7.6
41.8
|
L
 30.4%
H
6.8
41.8
|
L
 -98.1%
H
5.1
966
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
184.4
|
5.1
|
L
 1.6%
H
4.9
5.1
|
L
 -3.6%
H
4.9
5.6
|
L
 -0.4%
H
4.6
6.9
|
L
 42.4%
H
3.1
7
|
L
 319.0%
H
1.4
9.2
|
L
 -11.8%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
197.0
|
2.0
|
L
 -11.0%
H
1.8
2.1
|
L
 -8.2%
H
1.8
2.6
|
L
 304%
H
0.4
3.9
|
L
 281.1%
H
0.4
3.9
|
L
 -19.5%
H
0.4
3.9
|
L
 -69.1%
H
0.4
9.0
|
L
 -99.1%
H
0.4
36.3
|
L
H
0.4
224.5
|
| RAPT Therapeutics Inc |
|
799.7
|
28.9
|
L
 -0.6%
H
27.8
29.3
|
L
 -4.5%
H
27.8
31.6
|
L
 -0.6%
H
24.3
42.4
|
L
 181.6%
H
8.8
42.4
|
L
 16.4%
H
5.7
42.4
|
L
 -81.3%
H
5.7
251.6
|
L
 -88.3%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
2,955.1
|
30.6
|
L
 -1.0%
H
29.4
30.8
|
L
 -11.5%
H
28.6
35.0
|
L
 3.0%
H
28.6
36.0
|
L
 10.1%
H
27
36.0
|
L
 -39.3%
H
25.8
53.0
|
L
 -12.7%
H
25.8
60.4
|
L
 -72.5%
H
25.8
179.7
|
L
 -70.5%
H
25.8
179.7
|
| Rocket Pharmaceuticals Inc |
|
353.7
|
3.2
|
L
 -1.9%
H
3.0
3.3
|
L
 -15.9%
H
3.0
3.9
|
L
 1.0%
H
3.0
4.5
|
L
 2.6%
H
2.8
4.5
|
L
 -81.6%
H
2.2
17.8
|
L
 -80.5%
H
2.2
32.5
|
L
 -89.0%
H
2.2
67.5
|
L
 -93.4%
H
2.2
67.5
|
| Regeneron Pharma |
|
69,106.0
|
657.5
|
L
 1.7%
H
641.0
658.2
|
L
 0.9%
H
625.1
658.2
|
L
 12.7%
H
541
664
|
L
 17.5%
H
541
664
|
L
 -20.3%
H
476.5
834.4
|
L
 -12.4%
H
476.5
1211.2
|
L
 13.8%
H
441
1211.2
|
L
 17.0%
H
271.4
1211.2
|
| Replimune Group Inc |
|
763.8
|
8.3
|
L
 -2.2%
H
8.0
8.6
|
L
 -14.6%
H
8.0
9.6
|
L
 78.7%
H
4.3
10.9
|
L
 51.6%
H
3.1
10.9
|
L
 -31.9%
H
2.7
17
|
L
 -52.8%
H
2.7
29.5
|
L
 -82.1%
H
2.7
54.9
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
2.3
|
1.0
|
L
 -3.0%
H
1.0
1.0
|
L
 -21.6%
H
1.0
1.3
|
L
 -32.9%
H
1.0
1.7
|
L
 -61.6%
H
1.0
2.9
|
L
 -97.6%
H
0.7
60.5
|
L
 -100.0%
H
0.7
16405.2
|
L
H
0.7
569016
|
L
H
0.7
569016
|
| Regencell Bioscience Holdings |
|
6,438.2
|
13.0
|
L
 -1.8%
H
12.6
13.3
|
L
 -21.8%
H
12.6
16.9
|
L
 -35.1%
H
12.6
20
|
L
 -1.2%
H
12.0
21.8
|
L
 6752.6%
H
0.1
83.6
|
L
 1760%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,039.4
|
142.8
|
L
 -1.5%
H
139.4
144.6
|
L
 -4.2%
H
139.4
151.3
|
L
 -2.1%
H
139.4
169.9
|
L
 25.8%
H
111.2
169.9
|
L
 -0.7%
H
103.0
182.5
|
L
 -17.0%
H
103.0
212.2
|
L
 -29.3%
H
103.0
327.3
|
L
 432.7%
H
20.1
327.3
|
| Regenxbio Inc |
|
579.4
|
11.2
|
L
 0.4%
H
10.8
11.3
|
L
 -12.2%
H
10.8
12.5
|
L
 6.7%
H
10.5
13.9
|
L
 41.9%
H
7.4
13.9
|
L
 0.2%
H
5.0
13.9
|
L
 -46.2%
H
5.0
28.8
|
L
 -62.6%
H
5.0
50.3
|
L
 -45.5%
H
5.0
85.1
|
| Rigel Pharmaceuticals |
|
638.7
|
35.2
|
L
 -2.6%
H
34.6
35.9
|
L
 11.4%
H
28.1
39.6
|
L
 19.3%
H
26.4
39.6
|
L
 15.6%
H
26.4
43.7
|
L
 127.9%
H
14.6
43.7
|
L
 4592%
H
0.7
43.7
|
L
 1243.1%
H
0.6
43.7
|
L
 1006.6%
H
0.6
43.7
|
| Relay Therapeutics Inc |
|
1,048.6
|
6.1
|
L
 -7.4%
H
6.0
6.7
|
L
 -15.3%
H
6.0
7.3
|
L
 3.8%
H
5.8
7.6
|
L
 73.4%
H
3.0
7.6
|
L
 -1.5%
H
1.8
7.6
|
L
 -70.3%
H
1.8
23.2
|
L
 -86.1%
H
1.8
64.4
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
88.0
|
2.7
|
L
 1.5%
H
2.4
2.7
|
L
 17.3%
H
2.2
2.9
|
L
 33.2%
H
1.8
2.9
|
L
 341.7%
H
0.6
2.9
|
L
 -18.7%
H
0.2
3.4
|
L
 -55.5%
H
0.2
7.2
|
L
 -91.7%
H
0.2
40
|
L
 -81.6%
H
0.2
54
|
| Avidity Biosciences Inc |
|
10,260.2
|
69.8
|
L
 0.1%
H
69.7
69.9
|
L
 0.0%
H
69.7
69.9
|
L
 48.8%
H
46.1
70.5
|
L
 47.0%
H
35.7
70.5
|
L
 47%
H
21.5
70.5
|
L
 427.1%
H
4.8
70.5
|
L
 149.6%
H
4.8
70.5
|
L
H
4.8
70.5
|
| TransCode Therapeutics Inc |
|
8.6
|
9.4
|
L
 1.5%
H
8.9
9.5
|
L
 -15.8%
H
8.9
11.1
|
L
 -22.8%
H
8.9
21.0
|
L
 -11.5%
H
8.9
21.0
|
L
 -97.8%
H
6.2
468.4
|
L
 -100.0%
H
6.2
864864
|
L
H
6.2
5174400
|
L
H
6.2
5174400
|
| RenovoRx Inc |
|
35.2
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -13.5%
H
0.9
1.1
|
L
 -21.3%
H
0.9
1.3
|
L
 -20%
H
0.8
1.5
|
L
 -9.4%
H
0.8
1.7
|
L
 -48.9%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences |
|
14,081.0
|
20.6
|
L
 0.2%
H
20.0
20.8
|
L
 3.2%
H
19.3
20.8
|
L
 27.9%
H
15.9
20.8
|
L
 78.5%
H
10.9
20.8
|
L
 75.3%
H
8.7
20.8
|
L
 266.3%
H
4.7
20.8
|
L
H
2.5
20.8
|
L
H
2.5
20.8
|
| Royalty Pharma plc Ordinary |
|
16,474.7
|
38.6
|
L
 -5.4%
H
38.4
40.1
|
L
 2.7%
H
36.0
41.2
|
L
 6.8%
H
35.2
41.2
|
L
 4.2%
H
34.1
41.2
|
L
 45.4%
H
24.1
41.2
|
L
 -9.0%
H
24.1
44.5
|
L
 -4.2%
H
24.1
53.2
|
L
H
24.1
56.5
|
| Repare Therapeutics Inc |
|
72.6
|
1.7
|
L
H
1.7
1.7
|
L
 -8.2%
H
1.7
1.9
|
L
 -7.1%
H
1.7
2.0
|
L
 11.2%
H
1.5
2.0
|
L
 -53.3%
H
0.9
4.1
|
L
 -88.1%
H
0.9
18.7
|
L
 -93.9%
H
0.9
46.4
|
L
H
0.9
46.4
|
| Revolution Medicines Inc |
|
11,794.4
|
61.0
|
L
 -0.6%
H
58.9
61.4
|
L
 3.7%
H
56.7
63.2
|
L
 31.0%
H
46.2
63.2
|
L
 74.6%
H
34.1
63.2
|
L
 3.2%
H
29.2
63.2
|
L
 208.6%
H
15.5
63.2
|
L
 82.1%
H
14.1
63.2
|
L
H
14.1
63.2
|
| Reviva Pharmaceuticals |
|
57.0
|
0.5
|
L
H
0.5
0.5
|
L
 -16.7%
H
0.5
0.7
|
L
 -40.5%
H
0.4
0.8
|
L
 16.3%
H
0.3
0.9
|
L
 -46.8%
H
0.3
4.3
|
L
 -91.4%
H
0.3
9.3
|
L
 -95.4%
H
0.3
15.1
|
L
H
0.3
15.1
|
| Recursion Pharmaceuticals Inc |
|
2,408.2
|
4.6
|
L
H
4.2
4.6
|
L
 -16.3%
H
4.2
5.8
|
L
 -11.7%
H
4.2
7.2
|
L
 -14.6%
H
4.2
7.2
|
L
 -33.3%
H
3.8
12.4
|
L
 -50.9%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharmaceuticals Inc |
|
6,693.6
|
100.3
|
L
 1.8%
H
95.3
102.2
|
L
 -11.8%
H
95.3
114.2
|
L
 0.5%
H
95.3
116
|
L
 8.5%
H
89.2
116
|
L
 57.0%
H
45.9
116
|
L
 339.7%
H
15.5
116
|
L
 338.9%
H
3.0
116
|
L
H
3.0
116
|
| Rezolute Inc |
|
997.7
|
10.8
|
L
 12.1%
H
9.2
10.9
|
L
 15.5%
H
8.5
10.9
|
L
 22.8%
H
7.8
10.9
|
L
 93.2%
H
5.5
10.9
|
L
 88.1%
H
2.2
10.9
|
L
 494.5%
H
0.7
10.9
|
L
 -47.6%
H
0.7
21.1
|
L
 -81.4%
H
0.7
100
|
| Redhill Biopharma ADR |
|
3.8
|
1.1
|
L
 -1.7%
H
1.1
1.2
|
L
 -12.3%
H
1.0
1.6
|
L
 -39.4%
H
1.0
2.1
|
L
 -2.6%
H
1.0
2.8
|
L
 -86.0%
H
1.0
8.8
|
L
 -99.8%
H
1.0
630
|
L
 -100.0%
H
1.0
11520
|
L
 -100.0%
H
1.0
16540
|
| SAB Biotherapeutics Inc |
|
33.3
|
3.2
|
L
 3.2%
H
3.0
3.2
|
L
 -1.5%
H
2.8
3.3
|
L
 36.8%
H
2.1
3.3
|
L
 43.5%
H
1.9
3.3
|
L
 -2.1%
H
1
6.6
|
L
 207.7%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana Biotechnology Inc |
|
1,065.4
|
4.1
|
L
 1.0%
H
3.7
4.2
|
L
 -17.4%
H
3.7
5
|
L
 -0.7%
H
3.7
6.6
|
L
 37.7%
H
2.8
6.6
|
L
 31.9%
H
1.3
7.3
|
L
 -10.3%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
143.0
|
3.0
|
L
H
2.8
3.0
|
L
 -9.2%
H
2.8
3.3
|
L
 -13.5%
H
2.8
5.0
|
L
 35.2%
H
2.0
5.0
|
L
 -88.6%
H
1.2
34.0
|
L
 -91.3%
H
1.2
45.4
|
L
 -72.3%
H
1.2
146.2
|
L
 -77.3%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
8.4
|
1.7
|
L
 -3.9%
H
1.7
1.8
|
L
 -2.8%
H
1.6
1.9
|
L
 2.4%
H
1.5
2.4
|
L
 22.9%
H
1.4
2.4
|
L
 -36.8%
H
1.2
3.9
|
L
 -97.5%
H
0.1
140
|
L
 -99.5%
H
0.1
6280
|
L
 -100.0%
H
0.1
300000
|
| Scilex Holding Company |
|
139.3
|
18.8
|
L
 11.0%
H
16.3
19.0
|
L
 14%
H
16.2
21
|
L
 3.2%
H
12.6
21
|
L
 18.5%
H
12.6
34.3
|
L
 1819.4%
H
0.2
34.3
|
L
 105.3%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|